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Abstract
My research was involved in the synthesis of heterocyclic compounds of medicinal
relevance. f irstly, we designed and synthesized a novel 2-pyridone precursor related to
ABT-719, a well-known antibacterial compound. An advanced intermediated was
reached, but difficulties in the last steps precluded the synthesis of the intended bicyclic
azaquinoline.
The second project focused on the synthesis of a small library of 28 compounds as Rho
kinase inhibitors. The core structure was an amino piperidine, which was diversified as
sulfonamides and amides. Modest activity was found with one ofthe compounds.
The third project was invoÏved in the synthesis of a series of monocyclic acylguanidines
as Na/H exchanger inhibitors. Biological testing identified four potent inhibitors.
Keywords: heterocvcle, 2-pyridone, DNA gyrase, piperidine, Rhokinase inhibitor,
acylguanidine, Na/H exchanger (N}IE-1) inhibitor.
Résumé
Ma recherche décrit la synthèse de composés hétérocycliques d’importance biologique. En
premier lieu, nous avons fait le design et la synthèse d’un nouvel analogue de type 2-
pyridone basé sur la structure d’un composé antibactérien bien connu, le ABT-719. Un
composé intermédiaire avancé a été atteint, mais des difficultés lors des dernières étapes ont
mené à l’abandon de 1’ azaquinoline bicyclique désirée.
Le deuxième projet décrit la synthèse d’une petite librairie de 28 produits consistant en deux
séries de dérivés sulfonamides et amides de pipéridines comme étant inhibiteurs de la Rho-
kinase. Une activité modeste a été trouvée avec un des analogues.
Le troisième projet consiste en la synthèse d’acylguanidines monocycliques comme
inhibiteurs potentiels de canaux NatH (Na/H échangeur, NFTE-1). Basé sur les structures
connues d’inhibiteurs NHE, nous avons synthétisé une petite librairie de dérivés
acylguanidines. Les analyses biologiques ont identifié quatre inhibiteurs potentiels.
Mots clefs: hétérocycle, 2-pyridone, ADN gyrase, pipéridine, Rhokinase inhibiteurs,
acylguanidine, Na7W échangeur (NHE- 1) inhibiteur.
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CHAPTER 1
Synthesis of a novel of 2-pyridone analogue
o
1
Like the quinolones, the 2-pyridones are DNA gyrase inhibitors. The mechanism ofC inhibiting bacteria by 2-pyridones is very similar to that ofthe quinolones.5
1.2 The inhibition mechanism ofquinolones
Quinolone-type dmgs have a unique capacity to trap the intennediate (DNA gate) by
stabilizing the enzyme-DNA complex as illustrated in Figure 1.2. More importantly, such a
process leads to the formation of a cleavable complex.
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figure 1.2 Schematic presentation of the catalytic ftmction of DNA gyrase and the
bactericidal effect of quinolone antibacterials (Reproduced ftom Shen, L.L. Adv in
Pharmacology, 1994, 29A, 285).
1.3 Mode of action of quinolones
A model for the inhibition of ONA gyrase is shown in Figure 1.3. Quinolone molecules are
shown as solid and hatched rectangles that represent the dmg self-association, and binding to
a gyrase-induced DNA site during the intermediate gate-opening step of DNA supercoiling
process via hydrogen bonds to the unpaired bases indicated by doted fines. Gyrase A subunits
[ Catalysis
flelaxed ONA Enzyme-DNA
Complex
Supetcoiled DNA
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ProieaseK
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(Cleavable Complox9
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1.1 DNA gyrase inhïbitors
DNA gyrase1 is a bacterial motor protein in a class known as topoisomerases, which is
responsible for controlling the topological properties of DNA (e.g. amount of supercoiling or
catenation). Most topoisomerases can relax supercoiled DNA, which is an energetically
favourable process. DNA gyrase is unique amongst this class enzyme, because it can
introduce supercoils as well remove them. Quinolones were new generarion broad-spectrum
antibacterial agents2 developed in 1980s’. The mechanism of action of quinolones is
inhibition ofDNA gyrase.3
Four-generations of quinolone drugs have been developed.4 First-generation drugs (e.g.,
nalidixic acid) achieve minimal serum levels. Second-generation quinolones (e.g.,
ciprofloxacin) have increased Gram-negative and systemic activity. Third-generation dmgs
(e.g., levofloxacin) have expanded activity against Gram-positive bacteria and atypical
pathogens. Fourth-generation quinolone drugs (currently only trovafloxacin) add significant
activity against anaerobes. We chose ciprofloxacin as a representative of quinolone and
compared its structure with 2-pyridone. Figure 1.1 shows that changing the position and
number ofnitrogen in ciprofloxacin can generate two structures related to 2-pyridones.
Quinolone
HN]
Ciprofloxacin
— N
4-H-4-oxoquinolizine
C Figure 1.1 Structures of core units of 4-quinolone and 2-pyridone
4-Pyridone 2-Pyridone
4-oxo-1 ,4-dihydro 6H-6-oxo-
naphthyridine pyrido[ I .2-a]pyrimidine
4-oxo-1 ,4-dihydroquinolone
2
form covalent bonds between Tyr-122 and the 5’ end of the DNA chain, and the subsequentC opening of the DNA chains along the 4-hp staggered cuts resuits in a locally denatured DNA
bubble, which is an ideal site for the drug to bind. When a relaxed DNA is used, ATP is
required for the induction of the drug-binding site. Dashed curves mimic the shape of the
DNA gyrase, a tetramer of two A and two B subunits as revealed by the electron microscope
image ofthe M Ïuteus enzyme. Figure 1.4 is a 3-dimensional presentation ofthe model.
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Figure 1.3 Head to tau association allows H-bonding to DNA (reproduced from Shen, L.L.
Adv in Fharmacology, 1994, 29A, 285)
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Figure 1.4 Inhibition 3D model for quinolone antihiotics (reproduced from Shen, LL. Adv in
Fharmacology, 1994, 29A, 285)
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1.4 2-Pyridone: A new quinolone analogue
In an effort to discover nove! antibacterials related to the known fluoroquinolones6 sucli as
ciprofloxacin,7 scientists at Abbott Laboratories explored the chemistry of new series. This
involved transposition of the nitrogen of 4-quinolones to the bridgehead position at C5
quinolone membering) yielding two nove! heterocyclic nuclei related to a 2-pyridone, 6H-6-
oxo-pyrido[ 1 ,2-a]pyrimidine and 4-H-4-oxoquinolizine (see figure 1.1), which had flot
previously been evaluated as antibacterial agents and were found to be potent inhibitors of
DNA gyrase. In addition, the so-called 2-pyridones also possess favorable physiochemical
and pharmacokinetic properties.8’9
ABT-719 is a potential antibiotic compound,’° which was synthesized by scientists at Abbott
Laboratories. The chemical structure of ABT-719 is similar to fluoroquinolone, the
difference being transfer of the N atom to position 5. The target compound, 8-chloro-l-
cyclopropyl-7-ftuoro-9-methyl-4-oxo-1, 4-dihydro-pyrido [1.2-a] pyrazine-3 -carboxylic acid
ethyl ester is a nove! class of 2-pyridone core compared to ABT-719 (figure 1.5), The main
difference is in the replacement of C-5. This leads to a 5-aza-isoquinolone-type structure.
FioH FOCH
ÇN‘à12 N2
H2N
1.1
A5T719 target compound
figure 1.5 Structures ofABT-719 and a target compound
.
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1.5 Synthesis of $-ChIoro-1-eycopropyJ-7-flnoro-9-methy1-4-oxo-4ll-pyrido[1 ,2a] -
pyrazïne-3-carboxylic acid ethyl ester
We envisaged the disconnections shown in Figure 1.6 for the synthesis of the bicyclic core.
A series of aromatic substitutious would lead to the C-2 branched acid, which would be
subjected to a Curtius rearrangement.
CiN2
>
ciNH2 “ ciC02H
CH3 CH3 R CH3 R
target compound
F
F FN
ROCN ROLF
CH3R CI
Figure 1.6 Retrosynthesis ofthe target compound
2,4,5,6-Tetrafluoro-3-chloro-pyridine was treated with lithium tert-butoxide to give two
regioisomeric products 1.2 and 1.311 (Scheme 1.1). The next step involved metallation of aryl
chloride by sec-butyl lithium followed by alkylation with methyl iodide to afford compound
1.4. The fluorine in the 6 position was substituted with hydrazine and the product was
oxidized to yield compound 1.5. The carbanion formed by treatment of a substituted
acetonitrile with LDA was then used to introduce carbon branching at position 2 to give 1.6.
Treatment of 1.6 with POC13 effected the cleavage of the OtBu group and the replacement by
chlorine to give 1.7. Hydrolysis of the nitrile group with ethanolic HC1 afforded the ester12
1.8, which was subsequently converted to the carboxylic acid 1.9.13
O
6
Scheme 1.1 Synthesis ofthe 2-pyridone analogue
1. NH.,NH,
2. 02, NaOH
66%
FN
t-Bu0’fF
0H3
1.5
LDA, THF,-78°C
RCH2CN
81 % (a)
83 % (b)
FN
tBuO(N
CH3 R
1.6 fa, b)
POCI3, DMF
CH2CI2, r.t
89 ¾
95%
FN
J1&yCN
CH3 R
1.7 f a, b)
HCI F-N O
N-oC2H5EtOH I
CH3 R89 % (a)
82%(b) 1.8(a,b)
The Curtius rearrangement 11, 14 was tried in the presence of DPPA and TEA. However,
heating the compound 1.10 in tert-butyl alcohol didn’t lead to compound 1.11. Using the
smaller methanol didn’t help to produce the carbamate (Scheme 1.2).
Unfortunately the standard conditions for a Curtius rearrangement (DPPA, Et3N) and heating
in t-BuOH failed ta give the desired rearranged N-Boc derivative 1.11, Even though can
obeserve the formation ofthe isocyanate by R spectraoscopy.
Scheme 1.2 Attempted Curtius rearrangement
0
9 DPPA, PhMe FN 9 t-BUOH
CIyoH Et3N CIf’N3
CH3R CH3R
1.9(a,b) 1.lOfa,b)
t-BuOH
F
N O
Cl NH-QBu-t
CH3 R
1.1 1(a,b)
F F Ot-Bu F
F.LN tert-BuOLi F.N + R..._LN sec-BuLI
Mel, -78°C-78°C t-BuO I F t-Bu01F
CI 90% ci ci 76% CH3
1.2 1.3
7:1
1.4
2N NaOH
b
MeOH
78 ¾ ta)
76 % (b)
F-N O
Cif’0H
a R=EtCH3 R
b,-<
1.9 (a, b)
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We therefore considered an alterative strategy as shown in Scheme 1.3. Compound 1.5 was
reacted with 1 ,3-dithiane in the presence of n-BuLi15 to give 4-tert-butoxy-2-(2-ethyl-
[1,3]dithian-2-yl)-5-fluoro-3-methyl-pyridine 1.12, which was alkylated by ethyl triflate afier
deprotonation by n-BuLi to give compound 1.13.16 Removal of the 1.3-dithiane with BF3
OEt2 in MeCN and H20’7 gave 1.14. Reduction of the ketone with NaBH4 gave alcohol
1.15,18 which was transformed to the azide 1.16 under Mitsunobu condition.19
Triphenylphosphine was employed to reduce2° the azide to give amine 1.17.
Scheme 1.3 Alternative methods
BF3 CEt2
MeCN H20
41 ¾
NaBH4
MeOH
84 %
target compound
e
We had effectively introduced the amino propyl group at C-2 of the pyridine nucleus by this
method of branching. The remaining was to construct the pyrazine unit en route to intended
target.
From compounds 1.14 and 1.17, we tried to prepare the six-membered ring using diethyl
malonate derivatives2la, b Unfortunately, we were flot successful in effecting the desired
condensations.
FN
tBu0N
CH3
1.5
S F
N n-BuLiTHF
F()
_____
s
____ __ ____
t-Bu0S t BuOF
n-BuLi, THF TfOEt, -78°C
61% CI-13 S
- 6H3 Ç
1.12 1.13
R
CH3
1.14
F
N DEAD, DPPA
Ph3P, THF
CH3 71%
1.15
00
F»N
PhP
CI
N
CH3 Ç 52 % - CH3
F
NoEt
H20 BuO2
CH3 Ç
1.16 1.17 1.1
8
Scheme 1.4 shows in one series of reactions where the ketone 1.14 was treated with diethyl
2-aminomalonate under acid catalysis. We envisaged formation of an imine followed by
cyclization. In a second attempt, we reacted the aminopropyl pyridone with diethyl 2-oxo-
malonate under acid catalysis, expecting to get the same imine. In both cases starting
materials 1.14 and 1.17 were recovered with and without the loss of the tert-Bu group. The
literature has hardly any precedence for the formation of the intended ring structure as shown
in Scheme 1.5.2223
Scheme 1.4 Attempts toward target compound 1.1
F 1. NaBH, MeOH
2.DEAD,DPPA
t-BuO Ph3P, THF t-BuO’j3. Ph3P, H20CH3 O CH3 NH2
31 %
1.14 1.17
00 00
p-TsO (cat) \ EtO0EtEtotOE,,,,4” (1) PhH, reflux
(1) PhMe reflux
orNH2 / (2) p-TsOH (cat) (2) DMSO, 140°C 0
PhMe
Eto o o EtC O
OEt
F
t-BuO ( t-SuO
H3 x
F
NOEt /
t-BuO
N
CH3
O O
F
NfOEt
CI
N
6H3 Ç
1.1
target compound
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Thus, starting from compound 1.18, the reaction was conducted under varying conditions
such as boiling glacial acetic acid or in polyphosphoric acid at 80 °C. hi no case compound
1.19 was formed. Aiso with diethyl oxalate oniy 1.20 was formed aithough the bicycle 1.19
is theoreticaily possible. (Scheme 1.5)
Scheme 1.5 Examples ofcyclization
÷ H3COC2H5
+ EtOLOEt
COOR
\\
1.19
COOR
COCOOEt
1.20
1.6 Conclusion
Although we were successful in preparing suitably functionalized pyridines, the construction
ofthe desired 6-azaisoquinoline nucleus could flot be achieved. It is possible that the pyridine
nitrogen is too weakly basic to affect cyciization as shown in Scheme 1.4.
1.7 General experimental notes
Melting points (mp) were measured on a Fisher-Johns apparatus, and they are uncorrected.
Unïess otherwise specified, ail non-aqueous reactions were carried out under a nitrogen
atmosphere, using oven-dried giassware, and ail reaction soivents were removed by rotary
evaporator. Ail solvents in dry reactions were distiiied over calcium hydride. Unless other
stated, the reagents were purchased from Aidrich Chemical Co.
Analytical thin layer chromatography (TLC) was performed using EM Reagent 0.25 mm
silica gel 60-F plates. Visualization of the deveioped chromatogram was performed by DV
J H
1.18
1.18
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absorbance. Nuclear magnetic resonance of proton spectra (1H NMR) and carbon-13 (3C
NMR) were recorded on a Bruker AMX-300, or Bruker AMX-400 spectrometer in a
deuterated solvent as indicated using the signal from the residual non-deuterated solvent,
CHC13 (H, = 7.27 ppm; C, = 77.23 ppm) as internai reference. Chemical shifts () and
coupling constants (J) are expressed in ppm (part per million) and Hz (Hertz), respectiveiy.
The abbreviations used for the description ofthe peaks are as follows: s, singiet; d, doublet; t,
triplet; m, multiplet; br, broad; dd, doublet of doublet; doublet of triplets. DEPT-135
experiments were performed routinely, methyl (CH3) and methine (CH) give positive signal
(+), methylene (CH2) gives a negative signal (-), and tertracarbon give no signal (0). Ail
chemical shifis are measured from the centre of the resolved peaks, the unresolved multiple
and broad peaks are normally indicated as a range.
Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were
respectively determined on a VG Micro Mass 1212 and a kratos MS-50 TCTA mass
spectrometer by using methods of desorption chemical ionization (Cl) or fast atom
bombardment (fAB).
Inftared (W) spectra were recorded on Perkin-Elmer fTR Paragon 1000 spectrophotometer
in a chloroform solution with a sodium chloride ceil, or mixture film with KBr. Only
characteristic peaks are reported.
Opticai rotations ([Œ]) were measured at room temperature using a Perkin-Eimer polarimeter,
modele 241 apparatus with a sodium lamp (wavelength of 589 nm) at ambient temperature
using a 10 cm-lenghtceil containing 1 mL of a solution prepared at the indicated
concentration (c, g /100 mL).
Chromatography
flasli cbromatography was done by general procedure using Kieselgel (Merck 9385, 230-400
mesh) silica gel. Thin Layer Chromatography (TLC) was performed using commercial
availabie glass plates coated with Silica Gel 60 f254 with 0.25 mm tbickness (Merck,
Kieselgel 60F254).
11
TLC visualization
C
DV 254 lamp was used to observe the DV visible compounds and to evaluate the
advancement of the reaction. Chemical visualization was donc using one of the following
solutions:
ta) Molybdate/Ceric sulfate solution.
Ammonium molybdate (VI) tetrahydrate: (NH4)6Mo7O24.4H20 50g
Ammonium cerium (W) sulfate dihydrate: (NH4)4Ce($04).2H20 20g
Concentratedd suiphuric acid: H2S04 200 mL
Distilled water: H20 1200 mL
(b) Ninhydrin solution.
Ninhydrin dihydrate 2 g
Butanol 600 mL
Acetic acid 18 mL
(c) KMnO4 solution.
A 10% aqueous solution ofKMnO4 was used with olefin compounds.
Reagents
CommerciaÏÏy available were purchased from Aldrich, Sigma or Lancaster and used without
further purification. Ail commercially unavailable reagents were prepared.
Solvents
EtOAc, Hexane, and dichloromethane (DCM) were distilled prior to chromatography and
general use.
Toluene, THF, DCM and ether were dried using the dry alumina column. Triethylamine,
diisopropylamine benzene and methanol were distilled over calcium hydride.
C
12
Ail reaction were carried out under argon. The entire flasks were flame-dried under vacuum.
Ail needles and syringes were dried under vacuum before to use. Yieids refer to
chromatographically pure products.
F
FN
t-BuOF
CI
4-tert-Butoxy-3-chloro-2, 5, 6-trïfluoropyridine (1.2)
A solution of tert-BuOLi (7.5 g, 93.7 mmol) in TifF (75m!) was cooied to —78 oc in a dry
ice/acetone bath. A solution of 2,4,5,6-tetrafluoro-3-chloropyridine (22.5 g, 84.9 mmol)
(Aldrich, 70% pure) mixed with 2,4,5,6-tetrafluoro-3-chloropyridine 30% in THF (45 mL)
was added dropwise. The reaction mixture was stirred for 2 h at —78 °C, then at ambient
temperature ovemight. The reddish brown mixture was concentrated at —30 °c, hexane
(lOOmL) and celite (-5 g) were added and the mixture was stirred for 30 min. The solid was
removed by filtration the solvent was removed under reduced pressure to yieid a colorless
liquid (18.4 g, 90%) as a mixture of 1.2 (4-butoxy, desired) and 1.3 (6-butoxy, undesired) in
ratios of 7:1. The two compounds couid be separated by flash coÏumn chromatography (ethyl
acetate:hexane 3:97) to get pure compound 1.2 (15.lg, 71%)
‘H NMR (400 MHz, CDC13) 6: 1.2 1.52 (s, 9H); 1.3: 1.61 (s, 9H);
‘3c NMR (400 MHz, CDcl3) 6: 163.9, 159.1, 150.7, 132.1, 104.3, 73.1, 28.4.
‘9F NMR (400 MHz, cDcl3) 6 (ppm): 1.2: -73.75 (dd, J = 14.2, 23.2 Hz, 1F), -89.71 (dd, J
= 14.2, 21.9 Hz, 1F), -152.42 (t, J= 22 Hz, 1F); 1.3: -74.95 (dd, J 9.0, 24.5 Hz, 1F), -
121.69 (dd, 1=9.0, 18.1 Hz, 1F), -162.47 (dd, 1= 18.1,24.5Hz, 1F).
MS (M): 239.03
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t-BuOF
CH,
4-tert-Butoxy-3-methyl-2, 5, 6-trifluoropyridine (1.4)
A 250mL three-necked flask equipped with a mechanical stiner, a graduated addition funnel
and a digital thermometer was charged with compound 1.2 (6.06 g, 0.0252 moi) and THF (23
mL). The internai temperature ofthe mixture was cooled to —70 oc using a dry ice / acetone
bath. A solution of sec-BuLi (24 ml, 1.3 M in cyclohexane, 0.03 13 mol) was added via
syringe to this above stirred solution over a period of 1.0 h. The speed of addition was
adjusted as to maintain an internai temperature between —61 to —70 °C. Afier the addition
was completed, stirring was continued for an additional 1 h in a dry ice / acetone bath. MeT
(2.38 ml, 0.0383 mol) was added over -15 mm, the lithium sait dissolved and the internai
temperature rose quickly to —39 °c. The mixture was stirred for 1 h at ambient temperature.
The reaction was quenched with saturated aqueous NRC1 (7 mL) and extracted with 100 mL
of ether. The extract was washed with water (1 x 25 mL), brine (2 x 15 mL), dried over
MgS04, and concentrated to give the crude product (7.15 g). This material was distilled
under reduced pressure to give 1.4 (4.2 1 g, 76%) as a pale yellow liquid, bp. 75-81 °C (7.5
mmHg). It was used without fiirther purification.
‘H NMR (400 MHz, CDC13) 6 2.12 (s, 3H), 1.47 (s, 9H).
‘3C NMR (400 MHz, CDCI3) 6 164.3, 161.0, 149.8, 130.6, 105.1, 71.1, 28.5. 11.5.
19F NMR) (400 MHz, CDC13) 6 -75.91 (dd, J= 15.0, 22.1 Hz, 1F), -93.17 (dd, J= 15.0, 22.1
Hz, 1F), -156.54 (m, 1F).
HRMS: c10H12F3N0 (M); calcd.: 219.0897; found: 219.0881.
FN
t-BuOF
CH,
e
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4-tert-Butoxy-2, 5-difluoro-3-methylpyridine (1.5)
.
A solution of 1.4 (4.2 g, 19.2 mmol) and hydrazine monohydrate (>98%, 2.33 ml, 0.048 mol)
in methanol (7.5 mL) was refluxed for 9 h. The methanol was removed and the residue was
dissolved in methylene chloride (10 mL) and washed with water (2 x 5 mL). Solvent was
distilled under reduced pressure, leading an orange ou. It was redissolved in methanol (21.3
mL). To this was added aqueous sodium hydroxide (20%, 11.3 mL), and air was passed
through the solution for 6 days with vigorous stirring. The methanol was removed under
vacuum at 30-35 °C, the residue was dissolved in ether (38 mL), washed with water (1 x 15
mL), 10% HCi (1 x 10 mL), saturated bnne (1 x 20 mL), and dried over MgSO4. The solvent
was removed and the residue was purified by flash chromatography (ethyl acetate:hexane
5:95) to afford 2.56 g of 1.5 (66.5%) as a colorless liquid.
‘H NMR (400 MHz, CDC13) 6 7.85 (br, H), 2.18 (d, J= 1.5 Hz, 3H), 1.43 (d, 1= 1.5 Hz,
9H).
13c NMR (400 MHz, CDCI3) 6 162.5, 158.2, 143.7, 135.4, 106.6, 75.1, 28.5, 11.3.
19F NMR (400 MHz, CDCY3) 6 -73.37 (d, J= 24.5, 1F), -142.17 (d, J= 24.5 Hz, 1F)
MS: 201.10.
HRMS: C10H13F7N0 (M); Calcd.: 201.1072; found: 201.108$.
F
t-Bu
2-(4-tert-Butoxy-5-ftuoro-3-methyl-2-pyridyl)-2-cyclopropylacetonitrile (1.6 a)
LDA xvas formed by adding n-BuLi (2.5 M in hexanes, 15 mL, 37.5 mmol), dropwise to a
stirred solution of diisopropylamine (5.15 mL, 73.5 mmol) in THF (15 mL) at —78 °C. The
reaction was allowed to stir at O °C for 15 min and then cooled to —7$ °C with a dry
ice/acetone bath. Cyclopropylacetonitrile (3.0 g, 37.0 mmol) in anhydrous 111F (7.5 mL) was
added over a period of 15 min to the above solution of LDA, keeping the internai
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temperature between —51 and —67 °C. The mixture was stirred for an additional 35 min at the
O same temperature. To the above solution, 1.5 (3.0 g, 14.9 mmol) in T (7.5 mL) was added
over 20 min maintaining an internai temperature of —65 to —71 °C. The cooling bath was
removed and stirring was continued for 30 min. When the temperature reached —30 °C, an
exothermic reaction was observed and the temperature rose quickly to 17 °c. The reaction
was quenched with saturated aqueous NH4ci (10 mL) and was extracted with ether (50 mL).
The extract was washed with saturated brine, dried over Mg$04 and concentrated. The
excess cyclopropylacetonitrile was removed at 40-45 oc at 0.2 mmllg. The residue was
purified by flash chromatography (ethyl acetate:hexane 5:95) to give 1.6a (3.25 g, 83%) as a
colorless liquid, which solidified on standing.
Mp. 52-54 °c.
‘II NMR (400 MHz, cDcl3) 8.29 (s, 1H), 3.75 (d, J= 7.16 Hz, 1H), 2.28 (s, 3H), 1.4$ (m,
1H), 1.42 (s, 9H), 0.73 (m, 1H), 0.63 (m, 1H), 0.50 (m, 2H).
13c NMR (400 MHz, CDC13) 157.1, 154.7, 153.4, 150.7, 149.9, 137.2, 85.3, 38.9, 29.6
HRMS: C15H20N20f (M+1); Calcd.: 263.1560; found: 263.1565.
F
t-Bu
oCN
2-(4-tert-Butoxy-5-lluoro-3-methyl-2-pyrïdyl)-butyronitrïle (1 .6b)
The procedure was same as 1.6a to give 1.6b as a colorless solid (0.$g, 81%)
1H NMR (400 MHz, Dl3) (ppm): 8.12 (s, 1H), 3.91 (t, 1=7.1, 1H), 2.13 (s, 3H), 1.85
(m, 2H), 1.30 (s, 9H), 0.82 (t, 1= 7.1 Hz, 3H).
‘3C-NMR (400 MHz, D13) (ppm): 154.9, 152.4, 150.9, 150.9, 149.6, 136.2, 84.6, 38.3,
29.3, 26.6, 12.7, 12.0.
HR1’IS: C14H20FN20F (M+1); calcd.: 251.1538; found: 251.1527.
16
o2-(4-Chloro-5-fluoro-3-methy)-2-pyridyl)-2-cyclopropylacetonitrile (1 .7a)
b a solution of 1.6a (2.25 g, 8.65 mmol) and DMF (3.4 mL, 43.9 mmol) in anhydrous
methylene chloride (19 mL), POCI3 (3.17 mL, 34.0 mmol) was added slowly with an ambient
temperature bath cooling since there was a delayed exothermic reaction. The solution was
stirred ovemight before being poured into crushed ice. (Caution: make sure POC13 is
consumed before doing the extraction!). The mixture was extracted with methylene chloride
(2 x 30 mL). The combined extracts were washed with water (lx 15 mL), saturated aqueous
NaHCO3 (lx 15 mL), water (2x 10 mL), dried over MgSO4, and concentrated. The product
was purifled by flash chromatography (ethyl acetate:hexane 1:4) to yield 1.7a as a pale
yellow solid (1.83 g, 95%).
Mp. 43—44°C
‘H NMR (400 MHz, CDC13) 8.39 (s, 1H), 3.80 (d, J= 8.0 Hz, 1H), 2.49 (s, 3H), 1.50 (m,
1H). 0.77 (m, 1H), 0.66 (m, 1H), 0.58 (m, 1H), 0.48 (m, 1H).
‘3C NMR (400 MHz, CDCY3) & 161.1, 158.2, 136.6, 133.1, 128.8, 117.7, 34.1, 29.3, 18.7,
13.7, 11.2.
HRMS: C1,H10C1FN2 (W); Calcd.: 224.0484; found: 224.0489.
F
CN
2-(4-Chloro-5-fluoro-3-methyl-2-pyridyl)-butyronitrïie (1 .7b)
The procedure was same as 1.6b to give 1.7b (0.72 g, $9 %)
o
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III NMR (400 MHz, CDCÎ3) (ppm): 8.39 (s, 1H). 4.06 (t, J 7 Hz, 2H), 2.45 (s, 3H), 2.1
(m, 1H), 1.1 (t,J=6.5Hz,3H).
‘3C-NMR (400 IV[Hz, CDC13) (ppm): 156.7, 154.1, 150.3, 135.9, 131.8, 119.8, 39.1, 26.7,
15.6, 12.8.
HRMS: C10H10C1FN2 (M); Calcd.: 213.0542; found: 213.0529.
F
CIOC2H5
Ethyl 2-(4-chloro-5-lluoro-3-methyl-2-pyridyl)-2-cyclopropylacetate (1 .8a)
A solution of 1.7a (1.36 g, 6.0 mmol) in ethanol (0.9 mL) was added to a solution ofethanol
(10 mL) saturated with HC1 gas (—4 g) at O °C, which was prepared by the dropwise addition
of concentrate H2S04 onto CaC12 The reaction was stirred for 3 h at O °C. To this solution
was added F120 (0.9 mL). The reaction was heated at 80 °C for 2 h. The mixture was poured
over ice to give a total volume of 40 mL. This solution was neutralized with 50% NaOH to
pH 8 while maintaining a temperature less than O °C. The solid was filtered, dissolved in
CH2l2, and the residual water layer removed. The organic layer was dried over MgSO4 and
evaporated and purified by flash chromatography (ethyl acetate:hexane 2:8) to provide 1.$a
as a pure tan solid (1.34 g, 82%).
H NMR (400 MHz, CDC13) & 8.36 (s, 1H), 3.23 (d, J= 9 Hz, 1H), 0.12 2.40 (s, 3H), 1.67
(m, 1H), 1.20 (t,J=z 7Hz, 3H), 0.0.76 (m, 1H), 0.53 (m, 1H), 0.38 (m, 1H), 0.12 (m, 1H).
‘3CNMR (400 MHz, CDC13) : 172.0, 156.1, 154.1, 153.5, 136.2, 132.7, 66.4, 45.9, 24.3,
18.9 15.8, 12.9.
HRMS: C13H15C1FN02 (M); Calcd.: 271.0871; found: 271.0904.
c
CIOEt
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2-(4-Chloro-5-fluoro-3-methyl-2-pyridyl)-butyric acid ethyl ester (1 .8b)
The procedure was same as 1.8a to give 1.$b (0.72 g, 89%)
1fl NMR (400 MHz, CDC13) 6: 8.35 (s, 1H). 4.10 (q, J= 6.3 Hz, 2H), 3.82 (d, J= 8.7 Hz,
1H), 2.44 (s, 3H), 2.09 (m, 1H), 1.95 (m, 1H), 1.21 (t, J= 6.5 Hz, 3H), 1.85 (t, J= 6.1 Hz)
13C NMR (400 MHz, CDCI3) 6: 172.62, 155.9, 154.4, 153.4, 135.4, 132.6. 61.3, 52.1, 24.8,
15.8, 14.5, 12.5.
RRMS: C12H15C1FN02 (M); Calcd.: 259.0834; found: 259.0849.
)H
2-(4-Chloro-5-fluoro-3-methyl-2-pyridyl)-2-cyclopropylacetic acid (1 .9a)
A solution of 1.Sa (1.34 g, 5.8 mmol) in 10% NaOH (10 mL) was heated to 90 oc for 2 h.
Afier cooling the residue was removed by filtration. The solution was adjusted to pH 5 with
18% HC1 at O °c and a white solid precipitated. The solid was collected by filtration and
dried under vacuum to give (0.98 g, 76%) of pure compound 1.9a.
‘H NMR (400 MHz, D20) 6: 8.12 (s, 1H), 2.94 (d, J= 9.9 Hz, 1H), 2.21 (s, 3H), 1.32(m,
1H), 0.59 (m, 1H), 0.36 (m, 1H), 0.34 (m, 1H), 0.06 (m, 1H).
‘3C-NMR (400 MHz, D70) 6: 172.5, 156.1, 154.3, 153.5, 135.4, 133.6, 23.7, 18.3, 15.0,
11.7.
HRMS: c11H11clFNo2 (M); Calcd.: 243.0594; found: 243.0613.
F
N O
COH
O
CL
c’-13
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2-(4-Chloro-5-fluoro-3-methyl-2-pyridyl)-butyric acïd (1 .9b)
The procedure was same as 1.9a to give 1.9b (0.68 g, 78%)
‘H NMR (400 MHz, CDC13) 6 8.35 (s, 1H), 4.06 (q, J= 7 Hz, 2H), 2.57 (s, 3H), 2.1 (m, 1H),
1.95 (m, 1H), 0.90 (t, J 6.2 Hz, 3H).
‘3C-NMR (400 MHz, CDCY3) 6 175.9, 156.2, 153.9, 153.7, 134.5, 134.3, 50.9, 26.6, 15.7,
12.2.
HRIVIS: C10H,,C1FNO2 (M); Calcd.: 231.0462; found: 231.0465.
F
CI N3
(4-Chloro-5-fluoro-3-methyl-2-pyridyl)-cyclopropyl-acetyl azide (1.1 Oa)
To a solution of acid 1.9a (243 mg, 1.0 mmol) in toluene (10 mL) at O °C was added
triethylamine (396 pL, 3.0 mmol) follow by diphenyÏphosphoryl azide (430 j.iL, 2.0 mmol).
The ice bath was removed and afier 1.5 h of stirring at the room temperature, the reaction
was diluted with ether and H20 solution 45 mL (5:1). The layers were separated, and the
aqueous layer was extracted with ether (2 x 15 mL). The combined organic layers were
washed with saturated aqueous NaHCO3 (10 mL) and saturated aqueous NaC1 (10 mL). The
organic layer was dried over MgSO4 and concentrated under reduced pressure to give crude
product, which was purified by a very short column (ethyl acetate:hexane 5:95) to give
1.lOa. (174 mg, 65%)
IR: i = 2139.1, 1725.9 cm’
‘II NMR (400 MHz, D20) 6: 8.4 (s, 1H), 3.2 (d, 2H), 2.4 (s, 3H), 1.7 (m, 2H), 1.24 (2 H),
0.8 (m, 1H), 0.27 (m, 1H).
‘3C-NMR (400 MHz, D20) 6: 172.5, 156.1, 154.3, 153.5, 135.4, 133.6, 15.0, 12.9, 5.2, 3.8.
.
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CH3 H
4-tert-Butoxy-2- [1,31 dithian-2-yl-5-fluoro-3-methyl-pyridine (1.12)
A solution of 1,3-dithiane (0.7$ g, 6.5 mmol) in TRF (degassed with argon, 6.5 mL) was
cooled to —45°C and n-butyl lithium (hexane, 2.62 mL, 6.5 mmol) was added dropwise over
15 min. the reaction mixture was stirred for 2 h at —40 °C and then for 2 h at O °C. The
solution was cooled to —40 °C and the pyridine 1.5 (0.41 g, 2.2 mmol) was added dropwise,
then stirred for 2 h at —40 °C. The reaction mixture was quenched by the addition of aqueous
NH4C1 and extracted with CH2C12 (50 mL x 3). The combined organic layers were dried over
Na2S04, concentrated under reduced pressure, and then purified by flash column
chromatography (ethyl acetate:hexane 15:85) to give 2-dithianyl pyridine 1.12 as a white
solid (0.43 g, 6 1%).
Mp. 125 oc
1H NMR (400 MHz, CDC13) 6: 6 8.27 (s, 1H), 5.32 (s, 1H), 3.02 (m, 4H), 2.36 (s, 3H), 2.15
(m, 1H), 2.01 (s, 1H), 1.39 (d,J 1.1 Hz, 9H).
13C-NMR (400 MHz, CDC13) 6 (ppm): 6 155.2, 153.35 149.5, 136.5, 129.4, 84.5, 51.7. 32.1,
29.47, 25.9, 12.8.
MS (M): 301.1, 245.0, 212.1, 160.0, 147.1, 106.0.
HRMS: C14H20FN0S2 (M); Calcd.: 301.097036; found: 301.097521.
4-tert-Butoxy-2-(2-ethyl- [1,3] dithian-2-yl)-5-fluoro-3-methyl-pyridine (1.13)
A solution of 2-dithianyl pyridine 1.12 (301 mg, 1 mmol) in THF (degassed with argon, 2.5
mL) was cooled to -78 °C, and n-butyl lithium (hexane, 550 iiL, 1.1 mmol) was added
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dropwise over 15 min. The resultant solution was stirred at -78 °C for 30 min and then TfOEt
(155 iiL, 1.2 mmol) was added. The mixture was stirred in —40 °C for 1h, the cold bath was
removed, the temperature was raised to O °C for 1h, when a dark red color was appeared.
Quenched the reaction by the addition of saturated NII4C1 solution, extracted with CH2CÏ2 (3
x 15 mL), washed with NaHCO3 and H20, dried over Na2SO4. Concentration in vacuo and
purification by flash chromatography (ethyl acetate:hexane 10:90) afforded 1.13 (148 mg,
45%) as a yellowish white solid.
Mp. 114°C
‘H NMR (400 MHz, CDC13) : 8.39 (s, 1H). 4.06 (q, J= 7 Hz, 2H), 3.23 (d, J= 9 Hz, 1H),
2.43 (s, 3H), 2.1 (m, 1H), 1.05 (t, J= 7 Hz, 3H)
‘3C NMR (400 MHz, CDC13) & 156.5, 153.9, 149.4, 137.2, 129.9, 85.2, 51.3, 41.2, 33.4,
29.7, 26.1, 13.0, 9.8.
MS (M): 329.1, 296.1, 273.1, 240.1, 216.1, 160.0, 1487.1, 106.0.
HRMS: C16H24FN0S2 (M); Calcd.: 329.1283; found: 329.1299.
t-Bi
1 -(4-tert-Butoxy-5-fluoro-3-methyl-2-pyrïdyl)-propan-1-mie (1.14)
Red mercuric oxide (432 mg, 2.0 mmol), boron trifluoride diethyl etherate (252 tL, 2.0
mmoÏ) and 15% aqueous tetrahydrofuran (10 mL/g of dithiane) were stirred vigorously in a
three-neck flask equipped with a dropping funnel and a nitrogen inlet tube. Compound 1.13
(330 mg, 1.0 mmol) was dissolved in the minimum ofTHF and was added via the dropping
funnel in the course of 10-15 min under nitrogen. Stin-ing was maintained for 10-20 min afler
addition was complete. The red mercuric oxide gradually dissolved and a white precipitate
appeared. Ethyl ether (5 mL) was then added, the precipitated saits were filtered, and the
ether was washed to pH 10 with saturated Na2CO3, and to neutrality with satd. NaC1, afler
drying over Na2SO4, the ether was evaporated under vacuum and purified by flash
chromatography (ethyl acetate hexane 7 93) to yield compound 114 (98 mg, 41%)
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‘H NMR (400 MHz, CDC13) : 8.2$ (s, 1H), 3.12 (dd, J= 6.4 Hz, 2H), 2.4, 3H), 1.40 (d, J
1.4 Hz, 9H), 1.14 (t, J= 6.3 Hz, 3H).
‘3C-NMR (400 MHz, CDC13) & 204.5, 155.8, 154.2, 150.9, 135.6, 133.6, 84.9, 33.77, 29.5,
13.8, 8.5.
HRMS: C13H18FN02 (M); Calcd.: 239.1349; found: 239.1357.
H
t-Bu(
1 -(4-tert-Butoxy-5-fluoro-3-methyl-2-pyridyl)-propan-1
-ol (1.15)
Sodium borohydnde (113.5 mg, 3.0 mmol) was added portionwise over 30 min to a cooled
(ice bath) stirring suspension of ketone 1.14 (120 mg, 0.5 mmol) in anhydrous MeOH (3
mL). Complete dissolution was obtained at the end of the addition. The ice bath was
removed, and stirring was continued for 8 h. Monitoring by TLC (20% acetone-hexane on
silica gel) conflrmed that the reaction had gone to completion. The reaction mixture was
concentrated to a residue that was diluted with H70 and extracted with CH2C12 (3 x 15 mL).
The organic extract were combined, dried over anhydrous Na2SO4, and concentrated to
colourless ou. The crude product was purified by flash chromatography (ethyl acetate:
hexane 1:4) to affordthe alcohol 1.15 (109 mg, 91%).
1fl NMR (400 MHz, CDCJ3) E,: 8.22 (s, 1H), 4.71 (s, 1H), 4.45 (m, 1H), 2.1$ (s, 3H), 1.72
(m, 1H), 1.53 (m, 1H), 1.41 (d, J= 1.3 Hz, 9H). 0.95 (t, J 6.2 Hz, 3H)
‘3C-NMR (400 MHz, CDC13) E,: 157.7, 154.9, 149.7, 134.8 127.5, 84.4, 71.4, 30.9, 29.5,
12.1, 10.1.
MS (M): 241.1, 212.1, 185.1, 156.0, 147.1
HRMS: C13H70FN07 (M); Calcd.: 241.147$; found: 241.1472
23
FtBuON3
2-(1 -Azido-propyl)-4-tert-butoxy-5-ftuoro-3-methyl-pyridine (1.16)
b a stirred solution of 1.15 (24 mg, 0.1 mmol), triphenylphosphine (52.4 mg, 0.2 mmol) and
diisopropyl azodicarboxylate (42 tL, 0.2 mmol) in dry THF, a solution of diphenylphos
phoryl azide (44 pi, 0.2 mmol) was added over a period of 15 minutes and stirring continued
for about 24 h. after which when the solvent was removed from the reaction mixture on a
rotary evaporator under reduced pressure. The thick oily liquid was purified by flash
chromatography (ethyl acetate:hexane 1:9) to afford 1.16 as a colourless liquid (37.5 mg,
71%).
1H NMR (400 MHz, CDC13) : 8.32 (s, 1H), 4.38 (t, J= 7.1 Hz, 1H), 2.28 (s, 3H), 2.04 (m,
2H), 1.43 (s, 9H). 0.97 (t, J 6.9 Hz, 3H)
13C-NMR (400 MHz, CDC13) : 157.2, 152.3, 149.7, 131.9, 128.4, 83.1, 71.3, 30.2, 29.1,
12.4, 11.4
HRI’IS: C13H19FN40 (M); Calcd.: 266.154$; found: 266.1521
F
t-BuO
H2
1 -(4-tert-Butoxy-5-fluoro-3-methyt-2-pyrîdyl)-propylamïne (1.17)
A mixture ofazide 1.16 (113.15 mg, 0.5 mmol), triphenylphosphine (262 mg, 1.0 mmol), and
water (1$ pi, 1.0 mmol) was stirred in THF (15 mL) for 24h. The mixture was concentrated
and the residual ou was purified by flash chromatography (CHC12:MeOH:NH4OH 85:14:1)
to give pyridine amine 1.17.
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1H NMR (400 MHz, CDC13) & 8.25 (s, 1H), 4.12 (m, 1H), 2.25 (s, 3H), 1.73 (m, 2H), 1.42
(d, J= 1.0 Hz, 9H). 0.89.
‘3C-NMR (400 IVIHz, CDC13) & 156.1, 154.7, 148.4, 131.3, 127.7, 83.2, 70.1, 30.9, 29.4,
11.7, 10.0.
HRMS: C13H21FN20 (M); Calcd.: 240.1627; found: 240.1639.
Attempted cyclization
A. From ketone 1.14
Commercial diethyl aminomalonate hydrochioride was converted to its free amine by stirring
in ethanol with excess potassium carbonate for about 1 h. The solids were then flltered and
the ethanol removed in vacuo. Diethyl aminomalonate was subsequently distilled at reduced
pressure (10 Torr) using a Kugelrohr apparatus. This material was stored in a reffigerator,
and it maintained its integrity for several days as determined by 1H N1VIR.
The aminomalonate (263 mg, 1.5 mmol) was dissolved in toluene (7.5 mL), the ketone 1.14
(583 mg, 1.5 mmcl) was added to the mixture, the reaction flask was fifted with a Dean-Stark
apparatus and heated to reflux. Afier 13 h, the mixture was cooled, and the toluene was
removed in vacuo. Afler column chromatography, starting material was recovered.
B. From amine 1.17
To a solution of compound 1.17 (264 mg, 1.1 mmcl) in benzene (3 OmL) were added diethyl
2-oxomalonate (161 jiL, 1.0 mmcl) andp-toluenesulfonic acid (9.5 mg, 0.05 mmcl) under an
argon atmosphere. The reaction mixture was heated at reflux for 20 h with azeotropic
removal. The solvent was evaporated, and the residue was purified with Kugelrohr
distillation to give 4-hydroxyl starting material derivative of 1.17 (loss of t-Bu).
25
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oCHAPTER 2
Synthesis of Rho kinase ïnhibîtors
o
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2.1 The mechanism of action of Y-27632 — an inhibitor of Ca2-sensitizing enzyme
Abnormal smooth muscle contractility may be a major cause of disease states such as
hypertension, and a smooth-muscle relaxant that modulates this process would be useful
therapeuticalÏy. Smooth-muscle contraction is regulated by the cytosolic Ca2 concentration
and by the Ca2 sensitivity of myofilaments. The former activates myosin light-chain kinase
and the latter is achieved partly by inhibition of myosin phosphatase. Calcium sensitization
of smooth muscle is mediated by a Rho-associated protein kinase in hypertension.1
N-_NH--
Y-27632
Figure 2.1 Structure of Y-27632
Narumiya and colleagues1 have identified a drug (Y-27632) that inhibits the activity of a
Ca2-sensitizing enzyme (Rho-associated kinase) leading to a reduction of high blood
pressure in experimental animals (figure 2.1) Activation of receptors coupled to certain
guanine-nucleotide-binding proteins G releases intracellular Ca2 that binds to calmodulin
(Cam), and this complex activates myosin light-chain kinase (MLCK). By phosphorylating
the regulatory light chain of myosin (MLC50) in smooth muscle, MLCK causes vascular
smooth muscle to contract and the lumen of blood vessels to narrow. Many of the same
receptors also activate RhoA and, with the help of guanine-nucleotide exchange factors
(GEFs), dissociate cytosolic RhoA-GDP from guanine-nucleotide dissociation inhibitor
(GDI). which allows the exchange of GTP for GDP on RhoA. The active RhoA-GTP
activates Rho-associated kinase, wbich phosphorylates and so inhibits-myosin phosphatase.
Myosin phosphatase dephosphorylates smooth-muscle myosin, causing the smooth muscle to
relax and blood vessels to dilate. Y-27632 inhibits Rho-associated kinase, thereby blocking
the inhibition of smooth muscle myosin phosphatase2 and Ca2 sensitization.3 Although Ca2
is the main activator of smooth-muscle contraction (through MLCK), the level of force can
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be modulated independently of it.4 figure 2.2 shows the mechanism of inhibition.5 We
wished to test the activity of a small library of substituted piperidines as Rho-kinase
inhibitors (figure 2.3).
2.2 Piperidïne derïvatives as potential inhibitors of Rho kinase
Based on the structure of Y-27632, we postulated that 1,3- and 1,4-substituted piperidine
derivatives might have inhibitory activity against Rho Kinase. The intended derivatives and
their provenance are shown in figure 2.3.
Figure 2.2 The mechanism of action of Y-27632 27632 — an inhibition of the activity of
2+ . .Ca -sensitizing enzyme (Reproduced from Somlyo, A. P. Nature, 1997, 389, 908).
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X = H, Ph
Y = S02R1; H
Z = H; S02R1; COR2
X=H
Y=H
Z = H; S02R1; COR2
The common starting material was cyclopentenone, which would undergo a proline catalyzed
Michael addition (sce 2.4) to give the corresponding adduct. Beckmann rearrangement would
then lead to the corresponding lactams. Using this synthetic strategy we prepared five
different piperidine cores as shown in figure 2.4. The sites of diversification are shown in
Figure 2.5.
oc
Ph..û
core-1
Boc.
N
NH2
cote-5
Boc
3XNH2
core-4
H
core-2
core-3
e Figure 2.4 Synthesis offive piperidine cores
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Figure 2.3 The target compounds
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Figure 2.5 Retrosynthesis of substituted piperidine derivatives
2.3 Synthesis of intermedïates
2.3.1 Synthesïs of traits 4-isopropy]-cyclohexanecarboxylic acid 2.4
Isopropyl benzoic acid was hydrogenated with platinum oxide to give the cis-4-isopropyl-
cyclohexanecarboxylic acid as the major product. Esterification, isomerization and
hydrolysis gave the desired trans carboxylic acid 2.46 as the major diasteremer
Scheme 2.1 Synthesis of trans 4-isopropyl-cyclohexanecarboxylic acid 2.4
NH2
.11
o==o
/
HNLH
HNL9
‘E
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1.Pt02/H2,AcOH + 1. NaH, 160°C
L] 2.p-TsOH, MeOH Ç(J 2.IN NaOH, MeOH
CO2H 78 % CO2CH3 CO2CH3 64 %
5 1
2.1 2.2
CO2H CO2H separable
1 : 6
2.3 2.4
2.3.2 Synthesis of trans-4-(trffluoromethyl)cyclohexanecarboxy]ic acid 2.8
Methyl 4-trifluoromethylbenzoate was reduced and hydrolyzed to afford the cis-4-(trifluoro-
methyl)cyclohexanecarboxylic acid 2.7 as a major product following a proceduce in the
patant literature.7 Reaction with thionyl chloride and treatment with sodium hydroxide
resulted in the ii-ans acid 2.8 as a major product.
Scheme 2.2 Synthesis of trans-4-(trifluoromethyl)cyclohexanecarboxylic acid 2.8
CF3 CF3 CF3 CF3 CF3
RhC/H, 5 bar
+
I NNaOH
+ d
CO2CH3 CO2CH3 CO2CH3 CO2H CO2H
2.5 2.6 2.7
2.8
CF3 CF3 CF3 CF3
__
+
3O%NaOH
+ Ç
coci coci CO2H CO2H
29 210 1 5
2.7 2.8 separabIe
o
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2.3.3 Synthesis of 4-(1-tert-butoxycarbonylaminoethyl)benzoic acid 2.14
Using optically pure 1 $-(4-bromophenyl) ethylamine, three steps8 were necessary to obtain
optically pure compound 2.13, which was protected9 with Boc2O to give compound 2.14.
Scheme 2.3 Synthesis of 4-(1-tert-butoxycarbonylamino-ethyl)-benzoic acid 2.14
Br Br CN(L CH3CoCi (L CuCN, DMF (L 6MEtO,-lO°C ÇJ 180°C,48h 11O°C,75h
81 % _L. quant.
- NH2 NHAc NHAc
2.11 2.12
COOH COOH(L1 Boc2O (L1
NaHCO3, MeOH
I HCI f
NH2 83 % NHBoc
2.13 2.14
2.3.4 Synthesis of trans (S)-(1-tert-butoxycarbonylaminoethyl) cyc]ohexanecarboxylic
acid 2.20
Compound 2.13 was reduced,’° isomerized and protected to give optically pure 2.20.
(Scheme 2.4)
Scheme 2.4 Synthesis of trans-(5)-4-(1-tert-butoxycarbonylaminoethyl) cyclohexanecar
boxylic acid 2.20
CO2H CO2H CO H CO2Na CO2Na
PtO/H
+ à 1NNaOH +
HCI HCI HCI
NH2 NH2 NH2 NH2 NH2
2.13 major minor minor major
2.15 2.16 2.17 2.18
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2.4 Synthesis of piperïdine derivatives
2.4.1 Michael addition and Beckmann rearrangement.
2-Nitropropane was introduced by Michael addition to 2-cyclopentenone catalyzed by L
proline to give enantioenriched 2.21,” which reacted with hydroxylamine to afford the oxime
2.23.12 Unfortunately the enantioselectivity of this reaction is mediocre compared to that
using cyclohexenone. Nevertheless, we proceeded with the modestly enriched mixture
towards the intended mini-library. Compound 2.23 was protected by p-TsC1,’2 and then
subjected to a Beckmann rearrangement’3 in the presence of A1203 to give a regioisomeric
mixture 2.25 and 2.26 in a proportion of 3:2 (Scheme 2.1). The stereochemistry indicated
relates to the enriched isomer (75: 25 RIS).
Scheme 2.5 Synthesis of 3- and 4- substituted 5-lactams
H
N NO2
O
HN
2.23 2.26
It is not possible to derive clear a mechanistic pathway,” but it is known that the proline
catalyzed addition in presence of 2,5-dimethylpiperazine shows a complex non-linear effect.
CO2Na CO2Na CO2H CO2H
H2 + H2
H20/Dioxane
HBoc HBoc
minor major (21 % for 3 steps) : 5
2.17 2.18 2.19 2.20
separable
+
O
CHCI3
L-proline, r.t
86%
NO
‘X2
2.21
(75:25)
NH2OH, HCI
2.22
95%
NOH NOTs HàNO2 TsCI 6NO2 A1203 OwPyridine, O °C toluene No2 ÷
‘ 92% ‘ 54%
ee 50 %
2.24 2.25
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L-Proline first reacts with 2-cyclopentenone to give an iminium ion, which is attacked by
nitropropane anion to give the R-product 2.21 as ffie major isomer. Although several
secondary and tertiary bases were used as additives, only trans-2,5-dimethylpiperiazine gave
a good ratio.
Scheme 2.6 Possible transition state model for the Michael addition
O
II CHCI3( 3 mol% proline
\_JI cat.
HN NH
C,
L >= H° 1 O6
2.21 75 25 2.21 (ee = 50 %)
Beckmann rearrangement in the presence of dry alumina’3 afforded two constitutional
isomeric 3-substituted and 4-substituted lactams because of the existing of Z and E two
conformations in the oxime. A plausible mechanism is shown in Scheme 2.7. The mechanism
involves conversion of the oxime hydroxyl group to a leaving group. Ionization and
migration then occur as a concerted process, with the group, which is anti to the leaving
group migrating. This resuits in formation of an iminium ion, which captures water.
Eventually, hydrolysis leads to the lactams 2.25 and 2.26.
Scheme 2.7 Mechanism of Beckmann rearrangement
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The structural arrangement was made from analysis of their ‘H NMR spectura. Thus the
major isomer 2.25 shows a doublet of doublets for the C-6 methylene hydrogens next to the
lactam NH. The minor isomer 2.26 showed a multiplet for the C-6 methylene hydrogens
2.4.2. Synthesis of piperidine cores.
2.4.2.1 Synthesis ofpiperidine cores 2.32 and 2.33
The mixture of 2.25 and 2.26 was derivatized with Boc2O to give separable N-protected
lactams’4 2.27 and 2.2$. The desired compound 2.27 was treated with a Grignard reagent’ to
open the ring to give compound 2.29. Treatment with TFA16 gave the imine 2.30, followed
by a 2-step reaction sequence protocol17’ to give the amino N-Boc piperidine core
compound 2.32. Reduction’7 in the presence of Pd-C afforded the nitropiperidine core
compound 2.33. The relative stereochemistry of the 2-phenyl substituent was flot determined,
but it can be assumed to be cis by analyzing the coupling constants ofbenzylic proton by ‘H
NMR,
Scheme 2.8 Synthesis ofpiperidine cores 2.32 and 2.33
+
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Boc\
N
+
X2
o
2.27 PhMgBr
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CH2CI2
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2.4.2.2 Synthesis of pïperidine core 2.39
The mixture of lactams 2.25 and 2.26 was protected19 with PMBCI to yield two separable
compounds 2.34 and 2.35. BH3•SMe22° followed by NaBH4 and NiC122’ reduced the major
product to amine 2.37. Protection of 2.37 with Boc2022 and deprotection23 of PMB lead to
compound 2.39. ($cheme 2.9)
$cheme 2.9 Synthesis ofpiperidine core 2.39
H o PMB o
HN NaH,THF PMBN)
iKN02÷ LJ,kNo2 PM:cL O OC LJN
c2
2
2.25 2.26 2.34 2.35
PMB PMB
2
BH3.SMe2 NaBH4, NICI2 Boc2O
THF, 70 °C /N02 MeOH ÇJ, /NH2 CH2CI2, r.t
81% 78% 93%
2.36 2.37
PMB H
PU-c, H2
NHBoc MeOH LJ NHBoc
68%
2.38 2.39
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2.4.2.3 Synthesis of piperidine cores 2.42 and 2.45
Compounds 2.42 and 2.45 were prepared using a 4-step sequence from 2.27 and 2.28 as
shown in Scheme 2.10. In this sequence the lactam was reduced with the borane
dimethylsulfide complex,2° the piperidine protected as the N-Boc derivative, and the nitro
group reduced to the corresponding amine in the presence ofPd-C and hydrogen.24
Scheme 2.10 Synthesis ofpiperidine cores 2.42 and 2.45
oc
1.HCO2H
ÇJ., NO2 2. BH3•SMe2
/K THF
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2.4.3 Synthesis of 3-substituted piperïdine derivatives 2.47, 2.49, 2.51, 2.54, and 2.57
Piperidine cores 2.32, 2.33, and 2.39 reacted with substituted benzenesulfonyl chlorides to
yield sulfonylamides25 2.46, 2.48, and 2.50, which were deprotected26 or reduced2’ to Ïead to
the desired 3-substituted piperidine derivatives 2.47 a-e, 2.49 a-e, and 2.51 a-e respectively
(Scheme 2.11).
Scheme 2.11 Synthesis of3-substituted piperidine derivatives 2.47, 2.49, and 2.51
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Core compound 2.42 was coupled27 with substituted benzoic acids and saturated carboxylic
acids to give compounds 2.52 f-k, which were deprotected and treated with iN HC128 to give
hydrochioride saits 2.54 f-k. (Scheme 2.12)
Scheme 2.12 Synthesis of3-substituted piperidine derivatives 2.54
Boc Boc H
N DIEA, EDC, HOBt, N HCO2H N o
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e
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• Core compounds 2.42 was reacted with sulfonyl chlorides to give compounds 2.55 1, m,
Deprotection and conversion to the hydrochioride sait gave 2.57 1, m (Scheme 2.13).
Scheme 2.13 Synthesis of3-substituted piperidine derivatives 2.57
Boc OC H
Et3N, CH2CI2 HCOH
R3SO2CI J><\NH_s_Ra r.t
r 2.56 I m
cote 2.42 2.55 I,m iN HC1 I
L_e.. 2.57 I,m HC1 sait
I m
2.4.4 Synthesis of 4-substïtuted piperïdine derivatives 2.60 and 2.63
Applying the same procedure that was used to prepare as 2.54 and 2.57 gave the 4-
substituted compounds 2.60 g-k and 2.63 1, m as hydrochioride salis (Scheme 2.14).
Scheme 2.14 Synthesis of 4-substituted piperidine derivatives 2.60 and 2.63
Boc\ Boc\
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_______
ii HCO2H HNt H-—R2NCNH DMF, R2CO2H, r.t NL<HCR2 82 ¾
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2.5 Biologïcal tests
C
The set of substituted piperidine derivatives was tested for inhibition of the Rho Kinase.29’ 30
Unfortunately only moderate inhibition was observed with 4-tert-butyl-N-[1-methyl-1-(6S-
phenyl-piperidin-3R-yl)-ethyl] -benzenesulfonamide, 2.47a.
H
Ph,
30 % inhibition at 10 tM
Figure 2.6 Moderately active compound
2.6 Conclusion
We have prepared a small library of substituted piperidines as N-acyl and N-acylsulfonyl
derivatives, starting with cyclopentenone using a recently developed Michael addition with
nitroalkances. These compounds were obtained as enantiomerically partly enriched isomers
(--50% ee colTesponding to a 75:25 ratio of enantiomers in the 3-substituted piperidine
series). Biological testing reveraled that only one analogue (2.47a) was moderately active as
a Rho Kinase inhibitor.
2.7 Experimental notes (See Chapterl)
For some compounds the carbon resonances do flot match the formulae due to signal overlap.
and
CO2CH3 CO2CH3
CIS trans
2.1 2.2
4-Isopropylcyclohexanecarboxylic acid methyl ester (2.1) and (2.2)
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Q Cuminic acid (1 g, 6.1 mmol) was hydrogenated in acetic acid (5 mL) in the presence ofplatinum oxide (50 mg) under 60 psi ofhydrogen at room temperature. The reaction mixtures
were continuously stirred for 2 h. The acetic acid was distilled off from the reaction mixture
under reduced pressure, and 0.95 g of the mixture of cis- and trans-4-isopropylcyclohexane-
carboxylic acid was obtained by distillation (113-116 °C, 1 mmHg). b a solution of this acid
and methanol (15 mL), a catalytic amount ofTsOH (10% wt) was added and the mixture was
refluxed until starting material disappeared. Evaporation of methanol gave an ou which was
purified by flash chromatography (ethyl acetate:hexane 5:95) to afford a mixture of 2.1 and
2.2 in aratio of 3:1 (0.88 g, 79%).
‘U NMR (400 MHz, CDC13): 3.60 (s, 3H), 2.58-2.14(m, 1H), 2.08-0.83 (m, 10H)
‘3C-NMR (400 MHz, cDcl3): 177.07(d), 51.84(d), 43.72(d), 43.50(d), 32.4(d), 29.40(d),
27.02(d), 20.29(d)
Ô02H
trans-4-(Isopropyl)cyctohexanecarboxylic acîd (2.4)
The mixture of esters 2.1 and 2.2 (0.8 5 g, 4.6 mmol) was isomerized in the presence of 60%
sodium hydride (18.5 mg, 0.46 mmol) at 150 °C without solvent for 2 h. Water (3 mL) was
carefully added to quench the reaction, extraction with CH2CI2 (3x 20 mL), drying over
anhydrous Na2S04 gave 0.78 g ofthe trans methyl ester 2.2 and cis methyl ester 2.1 in a ratio
of 6:1 afier distillation (64 °C, 0.7 mmHg). The methyl ester was dissolved in 4.2 mL of
methanol and hydrolyzed by 4.2 mL of 2 N NaOH for 10 min. The solution was acidified
with iN HCi to pH 2, and the powdery precipitate was fiÏtered. The crude product 2.3 and
2.4 was recrystallized from 80% MeOH aqueous to afford the trans acid 2.4 (0.49g, 64 %) as
a white solid.
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‘H NMR (400 MHz, CD3OD): 2.24 (tt, J= 12.24, J= 3.49 Hz, 1H), 2.04 (m, 2H), 1.81 (m,
2H), 1.40 (m, 3H), 1.04 (tt, J = 11.7, J= 4.1 Hz, 1H), 1.01 (m, 2H), 0.86 (d, J 6.8 Hz, 6H).
‘3C-NMR (400 MHz, CDC13): 6 183.46, 43.76, 43.61, 33.14, 29.39, 29.18, 20.15.
HRMS: CjoHisO2(M); Calcd.: 170.1307; found: 170.1302.
CF3
à
CO2H
trans-4-(Trifluoromethyl)cyclohexanecarboxylic acid (2.8)
A mixture of ethyl 4-trifluoromethylbenzoate (191 mg, 0.94 mrnol), 2 mL of ethanol and 40
mg of rhodiumlactivated charcoal (5%) was hydrogenated for 5 h under a pressure of 5 bar
and at a temperature of 60 °C. The mixture of ethyl ester 2.5 and 2.6 obtained afler removal
of the catalyst by filtration and removal of the solvent was suspended in 1 ml of water and
treated with 140 mg of 30% NaOH solution, and the mixture was briefly heated to boiling
and stirred at room temperature for 18 h. Acidification using hydrochioric acid gave the
carboxylic acid (119 mg, 65% overail yield) as a cis/trans mixture.
A mixture ofthis acid (110 mg, 0.6 mmol) and 300 1iL ofthionyl chloride were boiled for 48
h. Afier the excess thionyl chloride was removed by distillation, 1 mL of water and 200 tL of
30% NaOH solution were added, and the reaction mixture was stirred at 60 °C for 2 h.
Acidification and recrystallization from petroleum ether gave the pure trans-carboxylic acid
2.8 (78 mg, 71% overali yield) as a white solid.
Mp. 154-155 °c
1H NMR (400 MHz, CDC13): 6 2.70 (tt, J= 13.4, J= 4.3 Hz, 1H), 2.09 (tt, J 12.8, J= 4.1
Hz, 1H), 2.07 (m, 2H), 2.0 (m, 2H), 1.40 (m, 4H),
‘3C-1’iqR (400 M}lz, cDcl3): 6 176.3, 42.5, 41.42, 3.59, 27.5, 27.3.
HRMS: c8H11F3O2 (Mj; Calcd.: 196.0711; found: 196.0718.
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Br
NHAc
(S)-N-Ethanoyl-1 -(4-bromophenyl)ethylamine (2.11)
A solution of(5)-1-(4-bromophenyl)ethylamine (0.5 g, 2.5 mol) and triethylamine (0.44 mL,
3.1 nnnol) in anhydrous diethyl ether (100 mL) was cooled to O °C. Acetyl chloride (0.21
mL, 3.0 mmol) was added dropwise with vigorous stirring, the temperature being maintained
at O °C. After allowing the mixture to warm to room temperature, water (100 mL) was added
and the diethyl ether layer separated, washed with O.1M HC1 (200 mL) followed by water
(2x100 mL) and finally dried over potassium carbonate. The off-white solid residue obtained
after evaporation of the solvent was recrystallised from diethyl ether giving the titie
compound as colorless needle-Iike crystals (0.58 g, 81%)
Mp. 127—130°C
‘H NMR (400 MHz, CDC13): 7.44 (d, 1= 8.4 Hz, 2H), 7.1$ (d, J= 8.4 Hz, 2H), 5.86 (s,
1H), 5.06 (m, 1H), 1.97 (s, 3H), 1.79 (s, 3H), 1.45 (d, J 6.95 Hz, 3H)
‘3C-NMR (400 MHz, CDC13): 170.9, 141.4, 131.6, 129.3, 121.1, 47.7, 23.6, 18.3
CN
N HAc
(S)-N-Ethanoyl-1 - (4-cyanophenyl) ethylamine (2.12)
Copper (I) cyanide, CuCN (0.46 g, 2.6 mmol) was added to a solution of 2.11 (0.620 g, 4.9
mmol) in dry DMF (5 mL) and the suspension stirred vigorously at 180 °C for 4$ h. A clear
solution was obtained. The solvent was removed under reduced pressure and the residue
taken into 6M HC1 (20 mL). The resulting red-brown solution was extracted with
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dichioromethane (5x 25 mL) and the organic extracts subsequently washed wiffi water (100
mL) to give a colorless solution. The solvent was removed under reduced pressure to yield
the compound 2.12 as a colorless solid (0.35 g, 75%).
Mp. 187-189°C
‘H NMR (400 MHz, CD3OD): 7.67 (d, J= 8.18, 2H), 7.48 (d, J= 8.46 Hz, 2H), 5.0 (j), J=
1H), 4.89 (s, 1H), 1.97 (s, 3H), 1.43 (d, J= 7.09 Hz, 3H)
‘3C NMR (CD3OD): 171.5, 150.3, 132.5, 127.1, 118.8, 110.8, 46.5, 21.6, 21.2
IR (solid): y =2227 (CN), 1637 cm (C0)
CO2H
HCI
NH2
(S)-4-(1-Aminoethyl) benzoic acïd hydrochioride (2.13)
Compound 2.12 (0.3 5 g, 1.8 mmol) was dissolved in 6M HC1 (5 mL), and the solution heated
at 108 °C for 75 h. The solvent was removed under reduced pressure to give 2.13 as a
colorless solid (0.32 g), which was used in next step without purification.
IR (solid): y =1703 cm1 (C=O)
1 NMR (400 MHz, CD3OD): 8.13 (d, J= 8.23, 2H), 7.48 (d, J= 8.29 Hz, 2H), 4.60 (q, J=
3.64, 1H), 1.97 (s, 3H), 1.43 (d, J= 7.09 Hz, 3H)
‘3C NMR (CD3OD): 168.0, 143.5, 131.6, 130.6, 126.9, 51.0, 19.8
CO2H
Y
NHBoc
o
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(S)-4-(1-tert-Butoxycarbonylamino-ethyl)-benzoic acid (2.14)A mixture of2J3 (0.3 g, 1.49 mmol), (Boc)20 (0.44 g, 2.0 mmol) and NaHCO3 (0.38 g, 4.5
mmol) in MeOH (8 mL) was sonicated in a cleaning bath until the starting matenal was no
longer detected. The solids were filtered and the solvent evaporated. The addition of 5 mL of
ether caused the precipitation of smalÏ quantities of minerai solids. The process was repeated
to give compound 2.14 as a white solid (0.3 1 g, 83%)
‘H NMR (400 MHz, CD3OD): 7.98 (d, J= 8.26, 2H), 7.42 (d, J 8.12 Hz, 2H), 4.70 (q, J
3.44, 1H), 1.43 (s, 9H), 1.35 (d, J 6.3 Hz, 3H), 1.24 (s, 1H)‘3C NMR (CD3OD): 168.7, 156.6, 150.8, 129.9, 129.4, 125.9, 79.2, 65.4, 27.8. 21.9.
CO2H
à
NHBoc
trans-(S)-4-(1 -tert-Butoxycarbonylamino-ethyl)-cyclohexanecarboxylic acid (2.20)A solution of 2.13 (184 mg, 0.92 mmol) in iN HC1 (2 mL) was hydrogenated over Pt02 (20
mg) at room temperature and atmospheric pressure. The catalyst was filtered off, and the
solution was evaporated to dryness to give the crude products 2.15 and 2.16 (161 mg), which
were heated in an autoclave at 200 oc for 10 h in iN NaOH (5 mL). To the resulting solution
was added activated carbon (30 mg), the suspension fiÏtered and evaporated to give a mixture
of sodium carboxylate 2.18 (108 mg) as the trans as a major product, which could flot be
separated from the minor cis isomer. The crude product was used in the next step.The crude product (96 mg) was dissolved in 1.5 mL water. b the solution added a mixture
of (Boc)20 (327 mg, 1.5 mmol) and dioxane (1.8 mL), the reaction was stirred at room
temperature until starting material was disappeared. iN KHSO4 aqueous was added to adjust
the pH to 4 at O °c. Solvent was removed under reduced pressure to give 2.19 and 2.20,
which were separated by column chromatography (ethyl acetate:hexane 1:1) to give trans
compound 2.20 (53 mg, 21%) as a white soiid.
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‘H NMR (400 IVifiz, CD3OD): 6 3.42 (dd, J= 4.1, 13.1 Hz, 1H), 2.55 (m, 1H), 2.09 (m, 2H),
1.42 (s, 9H), 1.26 (m, 3H), 1.04 (d, 1=6.72 Hz, 3H),
13c NMR (400 MHz, CD3OD): 6 178.9, 15 8.1, 79.7, 50.9, 43.6, 40.9, 28.8, 27.7, 27.6, 26.9,
29.9, 18.5
MS (M): 271.18, 144.10, 88.04
HRMS: C14H25N,04 (M); Calcd.: 271.1784; found: 271.1792.
NNO2
÷ NO2
R-(+)-3-(2-Nïtropropane-2-yI)cyclopentanone (2.21) and 3-epïmer
A mixture of2-cycÏopenten-1-one (0.5 mL, 5.2 mmol), 2-nitropropane (1 mL, 11.0 mmol),
2,5-dimethylpiperazine (0.6 mL, 5.3 mmol), a catalytic amount of L-proline (20.2 mg, 0.2
mmol), and 0.1 mL of water was stirred in reagent grade chloroform previously passed
through a bed of Beckmann 1 grade basic alumina (40 mL) for 62 h at RI. The reaction
mixture was diluted with CH2C12 and washed with aqueous HCI (3%). The organic phrase
was dried with Na2$04, filtered, concentrated and chromatographed on a silica gel column
(ethyl acetate:hexane 1:5) to obtain a colorless ou (0.84 mg, 88%).
[aj u +21.3 (c 1.0, CHCÏ3, R: S = 75:25; 50% ee)
1H NMR (400 MHz, CDC13) 6 2.77 (m, 1H), 2.24 (m, 3H), 2.02 (m, 2H), 1.5$ (m, 1H), 1.54
(d, J= 5.42 Hz, 3H).
13C-NMR (400 MHz, CDC13) 6 216.1, 89.9, 46.0, 40.5, 38.9, 24.8, 23.8.
HRMS: C8H,4N03 (M+1); Calcd.: 172.0974; found: 172.0977.
NOH
NO
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R-(+)-3-(2-Nïtropropane-2-yI)cyclopentanoxime (2.23) and 3-epimer
A solution of compound 2.21 (4.9 g, 28.9 mmol) in ethanol (75 mL) containing
hydroxylamine hydrochioride (3.2 g, 44.5 mmol) and potassium hydroxide (3.1 g, 55 mmol
in 5 mL water) was stirred at room temperature for 2.5 h. The precipate was filtered and
washed with EtOAc. The solvent was removed under vacuum, the residue was partitioned
between ethyl acetate and water. The combined organic phase was washed with brine, dried
over anhydrous Na2SO4, filtered, and evaporated under vacuum to yield 2.23 (4.9 g, 92%,
E/Z mixture) as colorless solid.
[ŒJ D:233 (c 1.0, CHC13)
‘H NMR (400 MHz, CDC13): 2.67 (m, 2H), 2.40 (m, 2H), 2.22 (m, 2H), 1.92 (m, 1H), 1.60
(d,J 1.54 Hz, 6H)
‘3C-NMR (400 MHz, CDC13): 163.9, 89.9, 32.1, 26.5, 25.7, 23.1, 22.8
HRMS: C8H,5N203 (M+1); Calcd.: 187.1083; found: 187.1079
NOTs
NO2
R-(+)-3-(2-Nitropropane-2-yI)cyclopentan-O-p-tosytoxime (2.24) and 3-epimer
To a solution of 2.23 (3.55 g, 18.8 mmol) in pyridine (17.5 mL) at O °C was added p
toluenesulfonyl chloride (4.3 g, 22.5 mmol). The reaction mixture was stirred at 0-5 oc for 5
h, it was diluted with ethyl acetate (40 mL), washed with iN cold HCI, saturated NaHCO3
solution and brine, and dried over MgSO4. The solvent was removed under vacuum to obtain
an ou (6.1 g) which slowly solidified on standing. The compound 2.24 was used in the next
step without further purification.
[(LI D:22.4 (c 1.0, cHcl3)
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‘H NMR (400 Ivifiz, CDC13): 6 7.84 ( d, J= 7.05, 2H), 7.35 (d, J= 7.76, 2H), 2.81-2.30 (m,
5H), 2.45 (s, 3H), 1.94 (m, 1H), 1.56 (m, 1H), 1.57 (d, J= 5.25 Hz, 6H)
‘3C-NMR (400 MHz, CDC13): 6 173.6, 145.53, 132.9, 130.1, 129.2, 89.4, 47.6, 33.3, 31.6,
29.3, 26.8, 24.3, 22.1.
H O
il
U andX X
2.25 2.26
5R-(1 -Methyl-1-nïtro-ethyl)-piperïdin-2-one (2.25) and 4R-(1 -Methyl-1 -nitro-ethyl)
piperidin-2-one (2.26) and their 3-epimers
Compound 2.24 (0.5 g, 21 mmoi) was dissolved in 25 mL methanol, the mixture was
absorbed on basic Beckmann grade I alumina. Toluene 50 mL was added and the solution
was evaporated to dryness. The procedure was iterated several times until the starting
material disappeared. The alumina was filtered and washed with methanol until ail the
product was resulted. Removed the solvent to give yellow solid, which was punfied by silica
gel colunm chromatography (MeOH:CH2C12 5:95) to afford a mixture of 2.25 and 2.26 as a
white solid (201 mg, 45%),
The mixture was separated afler protection with (Boc)20, treatment with formic acid gave
pure compounds 2.25 and 2.26 respectively.
For (2.25) ‘H NMR (400 MHz, CDC13): 6 2.10 (s, 1H) 3.26 (dd, J= 1.76, 12.9 Hz, 1H), 3.16
(dd, Jr 1.81, 4.64 Hz, 1H), 2.51 (m, 2H), 2.37 (m, 1H), 1.98 (m, 1H), 1.61-1.57 (m, 1H),
1.60 (s, 3H), 1.59 (s, 3H), ‘3C-NMR (400 Mhz, CDCI3): 6 174.3, 89.9, 43.1, 42.2, 31.2,
23.8, 23.7, 22.8; HRMS: C,8H,5N203 (M+1); Calcd.: 187.1085; found: 187.1083
For (2.26) 1H NMR (400 MHz, CDC13): 6 7.9 (s, 1H), 3.37 (m, 1H), 3.25 (m, 1H), 2.44 (dd,
J 1.86, 13.2 Hz, 1H), 2.37 (dd, J= 1.75, 4.8 Hz, 1H), 2.25 (m, 1H), 1.78 (m, 1H), 1.62 (m,
1H), 1.56 (s, 3H), 1.54 (s, 3H), 1.52 (m, 1H); ‘3C-NMR (400 MHz, CDC13): 6 174.4, 89.9,
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42.9, 41.8, 30.7, 23.8, 22.6, 22.3; IIRMS: C18H15N203 (M+1); Calcd.: 187.1087; found:
187.1085.
Boc Q
O
.j BocU
XN02
and NU
2.27 2.28
5R-(1 -Methyl-1 -nitro-ethyl)-2-oxo-piperidine-1-carboxylic acid tert-butyl ester (2.27)
and 4R-(1 -Methyl-1 -nïtro-ethyl)-2-oxo-pïperidine-1-carboxylic acid tert-butyl ester
(2.28) and their epimer
To a solution of mixture of 2.25 and 2.26 (0.93 mg, 5 mmol) in anhydrous CH2CÏ2 (25 mL)
were added Et3N (0.7 mL, 5.0 mmol), (Boc) 20 (0.6 mg, 6.0 mmol), and DMAP (60 mg, 0.5
mmol) at room temperature. Afier stirring for 18 h at r.t, the solvent was evaporated and
water (45 mL) was added. The resulting mixture was extracted with Et20 (3x 30 mL), the
combined organic layers were washed with 1 M KHSO4, NaHCO3, brine, and dried over
Na2SO4. After filtration and evaporation of the solvent, the mixture was separated by silica
gel column chromatography (ethyl acetate:hexane 1:4) to give N-Boc lactams 2.27 and 2.28
(0.69 g and 0.5 g respectively 88%) as white solids.
For (2.27) ‘H NMR (400 IVifiz, CDC13): 6 3.77 (dd, J= 1.81, 13.27, 1H), 3.42 (dd, J 1.79,
4.70 Hz, 1H), 2.6 (m, 2H), 2.40 (m, 1H), 1.85 (m, 1H), 1.61 (s, 3H), 1.59 (s, 3H), 1.57 (m,
1H), 1.47(s, 9H); ‘3C-NMR (400 Ivifiz, CDC13): 6 171.0, 152.4, 90.4, 83.9, 45.5, 41.9, 33.9,
28.0, 23.5, 23.0, 21.5; HRMS: C,3H23N205 (M+1); Calcd.: 287.1607; found: 287.1604.
For (2.28) ‘H NMR (400 IvIHz, CDC13): 6 3.86 (m, 1H), 3.49 (m, 1H), 2.57 (dd, J 14.82,
2.99, 2H), 2.30 (m, 1H), 1.87 (m, 1H), 1.55 (s, 6H), 1.50 (d, J= 3.31 Hz, 9H), 1.55-1.43 (m,
1H); 13C-NMR (400 MHz, CDC13): 6 169.5, 152.3, 90.5, 83.6, 45.0, 40.9, 36.3, 28.1, 24.6,
23.7, 22.2; HRMS: C,3H23N205 (M+1); Calcd.: 287.1607; found: 287.1612.
o
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[2R-(1-Methyl-1-nitro-ethyl)-5-oxo-5-phenyl-pentylJ-carbonic acid tert-butyl ester (2.29)
To a solution of compound 2.27 (464 mg, 1.62 mmol) in anhydrous THF (12 mL) under
argon was added dropwise a 1.0 M PhMgBr (2.5 mL, 2.5 mmol) at -78 °C. The reaction
mixture was slowly warmed to r.t and ovemight, and then quenched with H20 (5 mL). The
organic phase was extracted with EtOAc (3 x 10 mL), dried over Na2SO4. The solution was
evaporated and subjected to flash chromatography eluting with (ethyl acetate/hexane 1:9) to
give 2.29 as a white solid (413 mg, 70%).
‘H NMR (400 MHz, CDC13): 7.96 (d, J= 8.02 Hz, 2H), 7.59-7.43 (m, 4H), 5.3 (m, 1H),
4.9 (s, 1H), 4.42 (m, 1H), 3.32-3.1 (m, 4H), 1.60 (s, 3H), 1.58 (s, 3H), 1.46 (m, 1H) 1.41 (s,
9H)
13C-NMR (400 MHz, CDCI3): 199.9, 156.1, 133.5, 128.9, 128.3, 125.6, 91.7, 79.8, 47.0,
40.9, 36.9, 28.5, 27.9, 24.0, 23.8
HRMS: C,9H79N205 (M+1); Calcd.: 364.1281; found: 364.1299.
3R-(1 -Methyl-1 -nïtro-ethyl)-6-phenyl-2, 3,4,5-tetrahydro-pyridine (2.30) and 3-epimers
Trifluoroacetic acid (1 mL) was added dropwise to the 2.29 (364 mg, 1.0 mmol) with stirring
at O °C. The solution is stirred at room temperature ovemight until the starting material
disappeared, and then a 30% aqueous solution of sodium hydroxide was carefully added,
with cooling at O °c, until pH 10-11 was reached. The organic base was extracted with
CH212 (3x 10 mL), washed with brine, dried over Na2SO4, and evaporated. The crude imine
N HBoc
KNO2
.
e
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was purified by flash chromatography (ethyl acetate:hexane 1:4) to give 2.30 as a white solid
(206 mg, 84%)
1H NMR (400 MHz, CDC13): 7.75 (m, 2H), 7.38 (m, 3H), 4.0 (m, 1H), 3.48 (m, 1H), 2.89
(m, 1H), 2.63 (m, 1H), 2.37 (m, 1H), 1.81 (m, 1H), 1.63 (s, 3H), 1.60 (s, 3H), 1.58-1.47 (m,
1H).
‘3C-NMR (400 MEz, CDC13): 165.5, 139.2, 130.0, 128.4, 126.1, 90.7, 50.6, 41.5, 28.1,
24.1, 22.1, 21.4.
MS (Mj: 246.1, 216.1, 200.1, 171.1, 148.1.HRMS: C14H18N202 (M); Calcd.: 246.136$; found: 246.1377
t.
___,J 1,
5R-(1
-Methyl-1-nitro-ethyl)-2R-phenyl-piperïdine-1-carboxylic acid tert-butyl ester
(2.3 1)
To a solution of compound 2.30 (123 mg, 0.5 mmol) and EtOAc (5 mL) were added 10%
PdJC (0.20 g) and (Boc)20 (163 mg, 0.75 mmol), ami hydrogenated at atmosphere overnight
until the reaction was completed. The cataÏyst was filtered, and the solvent was removed
under reduce pressure to give a crude product, which was purified by flash cbromatography
(ethyl acetate:hexane 1:4) to give 2.31 as a white solid (158 mg, 9 1%). The relative stereo
chemistry was assumed to be cis.
1H NMR (400 MHz, CDC13): 6 7.32-7.14 (m, 5H), 4.78 (dd, J= 1.9, 10.58 Hz, 1H), 4.01
(dd, 1= 1.87, 14.90 Hz, 1H), 3.41 (dd, J= 1.78, 5.0 Hz, 1H), 2.62 (m, 1H), 2.20 (m, 1H),
1.72 (m, 2H), 1.65 (s, 3H), 1.57 (s, 3H), 1.56-1.29 (m, 1H), 1.29 (s, 9H), 1.29 (m, 1H).
‘3C-NMR (400 MHz, CDCÏ3): 6 155.0, 143.6, 128.3, 126.6, 124.9, 91.6, 79.8, 57.1, 42.7,
38.7, 29.1, 28.2, 28.0, 23.2, 21.7, 21.1.HRMS: C19H28N204 (M); Calcd.: 348.2049; found: 348.2041.
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o5R-(1 -Amino-1-metliyl-ethyl)-2R-phenyl-piperidine-1 -carboxylic acid tert-butyl ester
(2.32)
To a solution ofNiCl2•6H20 (124 mg, 0.52 mmol) in MeOH (2 mL) was added NaBH4 (316
mg, 8.36 mmol) in small portions. Afler stirring for 0.5 h (sonication) compound 2.31 (348
mg, 1.0 mmol) was added. And the mixture was filtered through a short pad of Celite afier 10
minutes. The Celite was washed with MeOH, and combined MeOH solution was
concentrated. Addition of iN NaOH to the residue, extraction with ether, and condensation
of the ether layer gave the amine derivative 2.32 (262 mg, 84%), whicli was used without
further purification.
1H NMR (400 MHz, CDC13): 7.32-7.16 (m, 5H), 4.78 (m, 1H), 4.01 (m, 1H), 3.43 (m, 1H),
2.63 (m, 1H), 2.14 (m, 1H), 1.75-1.56 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.43 (m, 1H), 1.29
(s, 9H), 1.29 (m, 1H),
‘3C-NMR (400 MHz, CDC13): 155.7, 144.1, 129.1, 127.8, 125.4, 92.2, 80.5, 57.6, 43.3,
39.4, 29.7, 28.8, 24.1, 22.2, 21.6.
HRMS: C19H30N202 (M); Calcd.: 318.2307; found: 318.2305
H
NO2
5R-(1 -Metliyl-1-nitro-ethyl)-2R-phenyt-piperidine (2.33)
To a solution of compound 2.30 (123 mg, 0.5 mmol) and EtOAc (5 mL), 10% PdJC (20 mg)
was added and hydrogenated at atmosphere ovemight until the reaction was completed. The
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catalyst was filtered, and the solvent was removed under reduce pressure. The residue was
purified by chromatography (MeOH!CH2C12 5:95) to give 2.33 as a white solid (116 mg, 94
‘11 NMR (400 MHz, CDC13): 7.34-7.25 (m, 5H), 3.56, (dd, J= 4.70, 11.2 Hz, 1H), 3.14
(dd, J= 4.3, 2.2 Hz, 1H), 2.28 (dd, J= 4.1, 1.9 Hz, 1H), 1.92 (m, 1H), 1.71 (m, 2H), 1.60 (s,
3H), 1.52 (s, 3H), 1.46 (m, 2H).
13C-NMR (400 MHz, CDCÏ3): 145.0, 128.9, 127.7, 126.9, 91.1, 62.2, 48.9, 45.7, 34.8,
27.0, 24.2, 26.8.
HR1’IS: C14H20N204 (M); Calcd.: 248.1527; found: 248.1523
PME
NO2
1 -(4-Methoxy-benzyl)-5R-(1-methyl-1-nitro-ethyl)-piperïdin-2-one (2.34)
b a solution of mixture of 2.25 and 2.26 (330 mg, 1.8 mmol) in 3.5 mL of THF was added
45.0 mg (1.89 mmol) ofNaH. The slurry was stirred for 15 mm, and a solution of 168 tL
(1.18 mmol) ofneat p-methoxylbenzyl chloride was added, followed by 72 mg (0.016 mmol)
oftetrabutylammonium iodide. The mixture was stirred for 21 h, and 1 mL of tert-BuOH was
added. 5 mL of 5 % NH4C1 was added slowly dropwise and the mixture was extracted with
diethyl ether (3 x 15 mL). The organic extracts were combined, washed with 10 mL of brine,
dried over Na2$04. Afier filtration and evaporation of the solvent, the mixture was separated
by silica gel colunm chromatography (ethyl acetate:hexane 3:7) to afford p-methoxybenzyl
lactams 2.34 and 2.35 (0.28 g and 0.19 g respectively 87%) as a pale yellow solids.
For (2.34) ‘11 NMR (400 IVifiz, CDC13): 6 7.16 (d, J 8.50 Hz, 2H), 6.85 (d, J 2.3 Hz,
2H), 6.84 (d, J= 8.60 Hz, 2H), 4.53 (dd, J= 14.52, 1.8 Hz, 1H), 4.47 (dd, J 4.9, 1.4 Hz,
1H), 3.78 (s, 3H), 3.06 (m, 1H), 2.58 (m, 1H), 2.45 (m, 2H), 1.80 (m, 1H), 1.55 (s, 3H),
1.50, (s, 1H), 1.19 (m, 1H); 13C-NMR (400 MHz, CDC13): 6 168.0, 159.5, 129.8, 129.3,
o
56
114.4, 90.6, 55.7, 49.8, 46.2, 42.0, 34.2, 25.0, 24.3, 22.0; HRMS: C6H22N2O4 (M+1),
Calcd.: 307.1658; found: 307.1652;
For (2.35) ‘11 NMR (400 MHz, CDC13): (5 7.21 (dd J 8.31 Hz, 2H), 6.92 (d, J 8.28 Hz,
2H), 6.71 (d, J= 8.1 Hz, 2H), 4.51 (m, 1H), 4.40 (m, 1H), 3.78 (s, 3H), 3.2 (m, 2H), 2.54 (m,
1H), 2.21 (m, 1H), 1.70 (m, 1H), 1.51 (s, 3H), 1.48 (s, 1H), 13C-NMR (400 IVIHz, CDC13): (5
168.0, 159.5, 129.9, 129.2, 114.3, 90.6, 55.7, 49.8, 46.2, 41.9, 34.2, 25.0, 24.3, 21.9; IIRMS:
C16H22N204 (M+1), Calcd.: 307.1656; found: 307.1654
PMB
1-(4-Methoxy-benzyl)-3R-(1-methyl-1-nitro-ethyl)-piperidine (2.36)
To a solution of 2.34 (306 mg, 1.0 mmol) in 2 mL of THF was added 1.1 mL (0.11 mmol) of
3H3•$Me2 (1 M in 111F). Afler the solution was stined at 70 °C for 2.5 h, the solvent was
removed, iN HC1 was added and the solution was refluxed 30 min then cooïed to O °C,
CH2C12 3mL and 0.5 mL of 1 N NaOH were added ana the solution was stirred for 20 mm,
washed with water, brine, and dried (Na2SO4) and concentrated Chromatography on silica
gel (ethyl acetate:hexane 1:9) using 5-20% ethyl acetate/hexane gave 2.36 (207 mg, 71%) as
a white solid.
1H NMR (400 IVifiz, CDC13): (57.14 (d, J= 8.34 Hz, 2H), 6.85 (d, J= 8.11 Hz, 2H), 3.7$ (s,
3H), 3.49 (d, 1= 13.06 Hz, 1H), 3.37 (d, J= 13.0 Hz, 1H), 2.81 (m, 2H), 2.2$ (m, 1H), 1.78-
1.54 (m, 5H), 1.52 (s, 3H), 1.51 (s, 1H), 1.04 (m, 1H)
‘3C-NMR (400 MHz, CDC13): (5 159.1, 130.5, 130.5, 114.0, 91.2, 63.1, 55.6, 55.4, 53.6,
45.4, 26.1, 25.6, 24.0, 23.7
MS (M+1): 292.1, 246.1, 154.0, 136.0, 121.0, 107.0, 77.0
HRMS: C19H29N205 (M+1); Calcd.: 292.1787; found: 292.1781
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PMB
fi
CJJNH2X
1- [1 -(4-Methoxy-benzyl)-piperidin-3R-yl]-1 -methyl-ethylamine (2.37)
To a solution ofNiCI26H2O (124 mg, 0.52 mmol) in MeOH (2 mL) was added NaBH4 (316
mg, 8.36 mmol) in small portions. Aller stirring for 0.5 h (sonication) compound 2.36 (292
mg, 1.0 mmol) was added, and the mixture was filtered through a short pad of Celite after 10
minutes. The Celite was washed with MeOH, and combined MeOH solution was
concentrated. Addition of iN NaOH to the residue, extraction with ether (3 x 20 mL), and
The organic extracts were combined, washed with brine, dried over Na2SO4. Aller
evaporation of the solvent, the crude was purified by column chromatography
(CH2C12:MeOH:NH4OH 85:14:1) to gave the amine derivative 2.37 (214 mg, 82%)
1H NMR (400 IVIHz, CDCÏ3): 7.18 (d, J= 8.28 Hz, 2H), 6.80 (d, J 8.36 Hz, 2H), 3.74 (s,
3H), 3.47 (d, J= 12.95 Hz, 1H), 3.0 (m, 1H), 2.78 (m, 1H), 2.34 (d, J= 12.0 Hz, 1H), 1.72
(m, 4H), 147 (m, 2H), 1.0 (s, 6H), 1.0 (m, 2H).
‘3C-NMR (400 MHz, CDC13): 158.9, 131.0, 130.6, 113.9, 63.6, 56.1, 55.6, 54.0, 51.0,
47.8, 29.2, 28.7, 26.2, 25.9.
MS (M+1): 262.2, 245.2, 231.2, 205.1, 141.1, 84.1.
HRI’vLS: C16H26N20 (M+1); Calcd.:262.2045; found: 262.2047.
PMB
HBoc
{1-[1-(4-Methoxy-benzyl)-piperidin-3R-yl]-1-methyi-ethyi}-carbamic acïd tert-butyl
ester (2.3$)
To a solution of the amine 2.37 (314 mg, 1.2 mmol) in CH2C12 (5 mL) was added Boc2O
(414 mg, 1.92 mmol) at room temperature, and the solution was stined for 24 h. The solution
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was concentrated, and the residue was purified by flash chromatography (ethyl
acetate:hexane 3:7) to afford 2.38 (311 mg, 86%) as white solid.
‘H NMR (400 MHz, CDC13): 7.22 (d, J= 8.49 Hz, 2H), 6.83 (d, J= 8.49 Hz, 2H), 3.7$ (s,
3H), 3.42 (s, 2H), 2.81 (m, 1H), 2.65 (m, 1H), 1.92 (m, 1H), 1.69 (m, 1H), 1.57-0.93 (m, 6H),
1.41 (s, 9H), 1.24 (s, 6H)
‘3C-NMR (400 MHz, CDC13): 158.4, 130.5, 129.9, 62.8, 55.2, 55.2, 54.3, 53.7, 43.7, 28.3,
25.5, 25.2, 24.9, 24.6.
MS (M+1): 363.2, 307.2, 204.1, 154.0, 121.0, 102.0.
HRMS: C21H35N203 (M+1); Calcd.: 363.2648; found: 363.263$.
H
N
NHB0c
X
(1-Methyl-1-piperidin-3R-yl-ethyl)-carbamic acid tert-butyl ester 2.39
An ethyl acetate solution of 2.38 (362 mg, 1.0 mmol) was treated with Pd(OH)2/C (37 mg)
and the mixture was stirred under a balloon containing hydrogen for 1.5 h. The reaction
mixture was filtered, rinsed with MeOH, the filtrate was concentrated and the residue was
chromatographed (MeOH: CH2C12 1:9) to afford 2.39 (196 mg, 80%) as a white solid.
‘H NMR (400 MHz, CDC13): 4.58, 2.96 (m, 1H), 2.87 (m, 1H), 2.34 (m, 4H), 1.66 (m,
3H), 1.30 (S, 9H), 1.08 (S, 1H), 1.07 (S, 3H)
‘3C-NMR (400 MHz, CDC13): 154.1, 78.2, 54.0, 47.7, 46.4, 44.7, 28.2, 26.9, 26.9, 24.5,
24.2.
HRMS: C13H26N207 (M); Calcd.: 242.2014; found: 242.2017
Boc
o
59
3R-(1 -Methyl-1 -nitro-ethyl)-piperidiue-1-carboxyfic acid tert-buty ester (2.41)
A solution of compound 2.27 (286 mg, 1 mmol) in formic acid (3 mL) was stirred for 1 h at
rt. Evaporation of the solvent under vacuum gave a solid, which was used in the next step
without purification. BH3SMe2 (0.6 mL, 2M in 111F) was added dropwise to a solution of
above preparation in 10 mL dry THF at room temperature. The reaction mixture was reftuxed
overnight. Afler removal of solvent, the residue was treated with 15 mL saturated HC1-
MeOH solution and refluxed for 30 min. The solvent was evaporated, 15 mL MeOH was
added and subsequentÏy removed under reduce pressure. The residue was further treated with
15 mL water and neutralized with K2C03, the aqueous suspension was extracted with three
portions of 15 mL dichloromethane. The combined extracts were dried over Na2SO4 and
evaporated to give the crude product 2.40 (163 mg, 95%).
b a solution ofthe 2.40 (163 mg, 0.95 mmol) in CH2C12 (5 mL) was added Boc2O (409 mg,
1.9 mmol) at room temperature, and the solution was stirred for 24 h. The solution was
concentrated, and the mixture was purified by flash chromatography (ethyl acetate:hexane
3:7) to afford 2.41 (233 mg, 86%) as a white solid.
‘H NMR (400 MHz, CDC13): 2.67 (m, 2H), 2.40 (m, 2H), 2.22 (m, 2H), 1.92 (m, 1H), 1.60
(d, J 1.54 Hz, 6H)
‘3C-NMR (400 MHz, CDC13): 155.0, 90.6, 80.2, 45.7, 45.0, 44.6, 28.7, 26.2, 25.5, 23.1,
21.7.
MS (M): 272.2, 217.1, 186.1, 168.1, 142.1, 130.1
HRMS: C13H74N204 (Mj; Cakd.: 272.1736; found: 272.1737
oc
3R-(1 -Amino-1 -methyl-ethyl)-piperïdîne-1 -carboxylic acid tert-butyl ester (2.42)
G
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A solution of 2.41 (326 mg, 1.2 mmol) in MeOH (6 mL) was hydrogenated over 10% Pd/C
(50 mg) at 60 psi at room temperature for 2 days until starting material was no longer
detectable by TLC. The reaction mixture was filtered through Celite, the pad was washed
with CH2C12 (5 mL), the solvent was removed and the residue was purified with column
chromatography (CH2CJ2:MeOH:NII4OH 90:9:1) to afford the desired product 2.42 as a
colorless ou (264 mg, 9 1%).
111 NMR (400 MHz, CDC13): 6 4.22 (b, 1H), 4.05 (b, 1H), 2.49 (m, 4H), 1.44 (s, 9H), 1.92
(m, 1H) 1.68 (m, 1H), 1.39-1.14 (m, 3H)
‘3C-NMR (400 MHz, CDC13): 155.2, 79.6, 52.0, 45.5, 44.0, 28.8, 28.2, 25.9, 24.1, 20.4.
MS (W): 242.2, 225.2, 184.1, 169.1, 72.1
IIRMS: C13H36N202 (W); Calcd.: 242.1994; found: 242.1993.
\ —n..
N
NO2
4-(1 -Methyl-1 -nitro-etliyl)-piperidine-1 -carboxylîc acid tert-butyl ester (2.44)
Using the same procedure as for 2.41 starting with 2.28 (286 mg, 1 mmol) afforded 2.44 (225
mg, 83 %).
1H NMR (400 MHz, CDC13): 6 4.10 (m, 2H), 2.5$ (m, 1H), 2.06 (m, 1H), 1.45 (s, 6H), 1.45-
1.37 (m, 2H), 1.37 (s, 9H).
‘3C-NMR (400 MHz, CDCI3): 154.9, 94.7, $0.0, 45.65, 28.74, 27.1, 27.4, 26.8.
MS (M): 272.2, 217.1, 186.1, 168.1, 142.1, 130.1.
IIRMS: C13H24N204 (M); Calcd.: 272.1734; found: 272.1739.
Bac
H2
4-(1 -Àmiuo-1 -methyl-etliyl)-piperidine-1-carboxylic acid tert-butyl ester (2.45)
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Using the same procedure as for 2.42 starting with 2.44 (286 mg, 1 mmol) afforded 2.45 (218
O mg, 90%).
‘H NMR (400 MHz, CDC13): 4.09 (b, 2H), 2.54 (m, 2H), 1.61 (m, 4H), 1.36 (s, 9H), 0.97
(s, 6H), 1.07 (m, 3H).
‘3C-NMR (400 M[{z, CDCÏ3): 155.1, 79.6, 51.6, 47.9, 40.1, 28.8, 28.3, 27.0.
MS (M): 242.2, 197.1, 72.1.
HRMS: C13H26N202 (M); Calcd.: 242.1994; found: 242.1999.
General procedure for the preparation of sulfonamides (A)
To a dry THF (6 ml) solution ofcrude amine (1.0 mmol) was added Et3N (0.4 mL, 3 mmol)
and the mixture were cooled to O °C. Benzenesulfonyl chloride (1.2 mmol) was added and the
solution was stirred at O °C for 10 min and then at room temperature for 24 h. Afler removal
of THF, water was added and the product was extracted with CH2CY2, washed with brine and
dried over Na2SO4, Condensation and purification by flash column chromatography (10-50%
ethyl acetate/hexane) afforded the product.
General procedure for the preparation of amides (B)
To a chilled solution of substituted benzoic acid (0.3 mmol), piperidine amine (48 mg, 0.2
mmol) and HOBt (46 mg, 0.3 mmol) in DMF (2mL) were added DWEA (52 pi, 0.3 mnrnl)
and EDC (58 mg, 0.3 mmol). Afier 1 h at O °C and 1 day at room temperature, the solution
was evaporated. The residue was added CH2C12 and washed with NaHCO3 and brine, dried
over Na2S04, and purified by flash column chromatography to give amide compounds.
Genereal procedure for reduction of nitro groups (C)
To a solution ofNiCl26H2O (124 mg, 0.52 mmol) in MeOH (2 ml) was added NaBH4 (316
mg, 8.36 mmol) in small portions. Afier stirring for 0.5 h (sonication) nitro compound (1.0
mmol) was added, and the mixture was filtered through a short pad of celite after 10 minutes.
The Celite was washed with MeOH, and combined MeOH solution was concentrated.
Addition of iN NaOH to the residue, which were extraction with ether, washing with brine
and drying over Na2SO4 gave a cmde product, which was purified by flash column
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Q chromatography (CH2Ci2:MeOH:NH3H2O 90:9:1) to give the amine derivatives as whitesolids.
General procedure for N-Boc hydrolysis (D)
Excess formic acid was added to ifie N-Boc protected compound. Formic acid was distilled,
the crude compound was purified with flash column chromatography (CH2Cl2:MeOH:NH3-
H20 90:9:1) to give amine derivatives as give final compounds.
General procedure for the preparation of hydrochioride saits (E)
HCÏ (1 N, 3.0 mmol) was dropped into a stirred suspension of piperidine derivatives (1.0
mmol) in H20 (5 mL). The filtered solution was frozen and then iyophilized to give the
hydrochioride sait as white solids
Q
5R- [1 -(4-tert-Butyl-benzenesulfonylamino)-1-methyl-ethylJ-2R-phenyl-piperidine-1-
carboxylic acïd tert-butyl ester (2.46a)
According to general procedure A, starting from 2.32 to give 2.46a (23 mg, 81 %).
‘H NMR (400 Mhz, CDC13): (3 7.86 (d, J= 8.2 Hz, 2H), 7.48 (d, J 8.1 Hz, 2H), 7.34-7.16
(m, 5H), 5.41 (s, 1H), 4.73 (m, 1H), 4.18 (m, 1H), 3.19 (dd, J= 6.8, 15.4 Hz, 1H), 2.14 (m,
1H), 1.90-1.78 (m, 2H), 1.521.58-1.39 (m, 2H), 1.39 (s, 9H), 1.3$ (s, 9H), 1.20 (s, 3H), 1.19
(s, 3H)
‘3C-NMR (400 MHz, CDC13): (3 156.3, 145.2, 136.8, 132.4, 128.7, 128.6, 127.1, 127.0,
125.8, 80.2, 58.5, 58.1, 41.2, 40.8, 30.9, 30.1, 28.9, 25.1, 24.6, 22.1
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5R- tl-Methyl-1-(3-trïfluorometliyl-benzeuesuffonylamino)-etliylJ-2R-phenyl-piperidine-
1-carboxylic acid tert-butyl ester (2.46b)
According to general procedure A, starting from 2.32 to give 2.46b (23 mg, 81 %)
‘H NMR (400 MHz, CDC13): 6 8.18 (s, 1H), 8.05 (dd J= 8.1, 6.9 Hz, 1H), 7.88 (m, 1H),
7.62 (t, J= 87.9 Hz, 1H), 7.738-7.17 (m, 5H), 5.92 (s, 1H), 4.80 (m, 1H), 4.19 (m, 1H), 3.21
(m, 1h), 2.15 (m, 1H), 1.79 (m, 2H), 1.52 (m, 1H), 1.27 (m, 1H), 1.37 (s, 9H), 1.24 (s, 3H),
1.18 (s, 3H)
‘3C-NMR (400 MHz, CDC13): 6 157.3, 143. 130.7, 130.1, 129.0, 129.0, 128.8, 127.2, 125.5,
124.7, 81.3, 59.4, 57.9, 46.6, 38.6, 30.0, 28.7, 28.0, 23.9, 21.4
5R- [1 -(4-Chloro-benzenesulfonylamino)-1-methyl-ethylJ-2R-phenyl-piperidine-1 -
carboxylic acid tert-butyl ester (2.46c)
According to general procedure A, starting from 2.32 to give 2.46c (23 mg, 81 %)
1fJ NMR (400 MHz, CDCÏ3): 6 7.88 (d, J= 8.27 Hz, 2H), 7.47 (d, J 8.23 Hz, 2H), 7.3 1-
7.17 (m, 5H), 5.65 (s, 1H), 4.78 (m, 12H), 4.15 (m, 1H), 3.12 (m, H), 2.19 (m, 1H), 1.81 (m,
21H0, 1.58-1.39 (m, 2H), 1.38 (s, 9H), 1.21 (s, 3H), 1.19 (s, 3H)
‘3C-NMR (400 MHz, CDC13): 6 158.3, 147.2, 144.1, 132.9, 132.4, 128.7, 127.4, 127.0,
126,2, 8 1.6, 59.2, 58.4, 46.7, 38.5, 30.0, 28.9, 27.14, 23.5, 22.1
o
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Q
5R-[1 -Methyl-1-(toluene-4-sulfonylamino)-ethylj-2R-phenyl-pïperidine-1-carboxylic
acid tert-butyl ester (2.46d)
According to general procedure A, starting from 2.32 to give 2.46d (23 mg, 8 1%).
1H NMR (400 IViliz, CDC13): 6 7.79 (d, J= 7.1 Hz, 2H), 7.29-7.23 (m, 5H), 7.17 (d, J 6.9
Hz), 5.36 (s, 1H), 4.78 (m, 1H), 4.16 (m, 1H), 3.48 (m, 2H), 3.21 (m, 1H), 2.42 (s, 3H), 2.16
(m, 1H), 1.84 (m, 2H), 1.52 (m, 2H), 1.35 (s, 9H), 1.23 (s, 3H), 1.16 (s, 3H), 1.16 (m, 1H).
13C-NMR (400 MHz, CDC13): 6 156.8, 145.8, 143.9, 132.1, 131.5, 128.8, 127.4, 127.2,
125.5, 81.1, 59.5, 57.9, 46.5, 38.7, 30.1, 28.7, 27.5, 23.7, 21.5.
Q
5R- [1 -(4-Methoxy-benzenesulfonylamino)-1-methyl-ethyl] -2R-phenyl-piperidine-1 -
carboxylïc acid tert-butyl ester (2.46e)
According to general procedure A, starting from 2.32 to give 2.46e (23 mg, 81%)
1H NMR (400 MHz, CDC13): 6 7.82 (d, J=z 8.1 Hz, 2H), 7.38-7.17 (m, 5H), 6.98 (d, J 8.2
Hz, 2H, J= 8.23 Hz, 2H), 5.40 (s, 1H), 4.78 (m, 1H), 4.15 (m, 1H), 3.27 (s, 3H), 3.20 (m,
1H), 2.18 (m, 1H), 1.83 (m, 2H), 1.57-1.39 (m, 2H), 1.34 (s, 9H), 1.28 (m, 1H), 1.22 (s, 3H),
1.16 (s, 3H)
13C-NMR (400 MHz, CDC13): 6 155.9, 145.0, 136.2, 131.6, 128.9, 128.8, 127.1, 127.0,
125.5, 80.1, 58.5, 57.6, 40.9, 39.4, 30.8, 28.6, 24.9, 24.1, 22.1
a
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o(2.47a)
Acording to general procedure D, starting ftom 2.46a to give 2.47a (23 mg, 81%)
‘H NMR (400 MHz, CDCI3): 7.82 (d, J= 8.2 Hz, 2H), 7.58 (d, J= 8.1 Hz, 2H), 7.37-7.2 1
(m, 5H), 4.9 (s, 1H), 3.50 (dd, J= 10.6, 1.8 Hz, 1H), 3.25 (m, 2H), 2.55 (m, 2H), 1.90 (m,
1H), 1.82 (m, 1H), 1.67 (m, 1H), 1.3 (s, 9H), 1.22 (s, 3H), 1.20 (s, 3H)
13C-NMR (400 MHz, CDCJ3): 156.3, 145.2, 140.9, 122.8, 127.6, 127.2, 127.0, 126.3, 62.2,
59.1, 48.8, 47.3, 35.5, 35.1, 3 1.5, 26.6, 25.7, 25.6
HR1’1S: C24H34N202S (M); Calcd.: 414.2341; found: 414.2338
N- [1 -Methyl-1 -(6R-phenyl-piperidin-3R-yl)-ethylJ-3-trifluoromethyl-benzenesulfon-
amide (2.47b)
According to general procedure D, starting from 2.46b to give 2.47b (23 mg, 84%)
‘H NMR (400 MHz, CDC13): 8.18 (s, 1H), 8.1 (dd, J= 8.0, 3.1 Hz, 1H), 7.81 (d, J 7.6
Hz, 1H), 7.65 (m, 1H), 7.37 (m, 5H), 4.7 (br, 1H), 3.52 (m, J = 11.4, 2.32 Hz, 1H), 3.27 (m,
1H), 2.57 (m, 1H), 1.94-1.72 (m, 3H), 1.48 (m, 1H), 1.29 (m, 1H), 1.23 (s, 3H), 1.21 (s, 3H)
‘3C-NMR (400 MHz, CDC13): 156.3, 145.2, 140.9, 129.9, 129.1, 128.3, 128.0, 127.6,
114.1, 61.2, 55.9, 46.9, 45.9, 33.3, 28.7, 27.9, 23.0
HRMS: C71H,5F3N202S (M); CaÏcd.: 426.1559; found: 426.1579
4-tert-Butyl-N- [1 -methyl-1 -(6R-phenyl-piperidin-3R-yI)-ethyl]-benzenesulfonamide
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4-Chloro-N- [1 -metliyl-1-(6R-phenyl-piperîdïn-3R-yl)-ethyl]-benzenesutfonamide (2.47c)
According to general procedure D, starting from 2.46c to give 2.47c (27 mg, 87%)
‘H NMR (400 MHz, CDC13): 7.8$ (d, J= 8.27 Hz, 2H), 7.47 (d, J 8.23 Hz, 2H), 7.30 (m,
5H), 3.54 (m, 1H), 3.33 (m, 1H), 2.57 (m, 1H), 1.90 (m, 2H), 1.82 (m, 1H), 1.52 (m, 1H),
1.30 (m, 1H), 1.20 (s, 3H), 1.19 (s, 3H)
‘3C-NMR (400 MHz, CDC13): 160.1, 142.5, 139.0, 129.6, 128.9, 128.8, 127.7, 127.1, 62.1,
59.5, 59.4, 48.5, 47.1, 26.4, 25.9, 25.1
HRMS: C20H25C1N202S (M); Calcd.: 393.1325; found: 393.1331
4-Methyl-N- [1 -methyl-1 -(6R-phenyl-piperidiu-3R-yl)-ethyl]-beuzenesulfonamide (2.47d)
According to general procedure D, starting from 2.46d to give 2.47d (19 mg, 87%)
‘H NMR (400 MHz, CDC13): 6 7.80 (d, J= 7.9 Hz, 2H), 7.40 (d, J=z 8.1 Hz, 2H), 7.39-7.27
(m, 5H), 5.40 (br, 1H), 3.64 (dd, J= 11.4, 3.1 Hz, 1H), 3.49 (m, 1H), 2.67 (m, 1H), 2.42 (s,
3H), 1.92 (m, 3H), 1.65 (m, 1H), 1.35 (m, 1H), 1.18 (s, 9H), 1.17 (s, 9H)
‘3C-NMR (400 MHz, CDC13): 6 156.7, 143.2, 141.1, 129.9, 129.0, 128.2, 127.3, 127.3,
61.8, 58.9, 46.1, 33.7, 26.1, 25.9, 24.5, 21.9
HRMS: C21H28N202S (M); Calcd.: 372.1872; found: 372.1871
67
Q4-Methoxy-N-[1 -methyl-1-(6R-phenyl-piperidin-3R-yI)-ethyl]-benzenesulfonamide
(2.47e)
According to general procedure D, starting from 2.46e to give 2.47e (18 mg, 84%)
1H NMR (400 MHz, CDC13): 6 7.83 (d, J= 8.9 Hz, 2H), 7.33-7.25 (m, 5H), 6.96 (d, J 8.9
Hz, 2H), 4.55 (s, 1H), 3.87 (s, 3H), 3.52 (dd, J= 11.3, 2.3 Hz, 1H), 3.29 (m, 1H), 2.57 (m,
1H), 1.96-1.86 (m, 2H), 1.68 (m, 1H), 1.32 (m, 1H), 1.21 (s, 3H), 1.20 (s, 3H)
‘3C-NMR (400 MHz, CDC13): 6 162.9, 135.6, 129.5, 128.9, 127.6, 127.0, 114.4, 62.3, 59.0
56.0, 48.7, 47.6, 35.1, 26.5, 25.7, 25.2
HRfvIS: C21H79N703S (Mj; calcd.: 388.1821; found: 388.1819
(2.48a)
According to general procedure A, starting from 2.33 to give 2.4$a (22 mg, 83%)
1H NMR (400 MHz, CDCI3): 6 7.26 (m, 4H), 7.09 (m, 5H), 4.25 (dd, J 9.20, 5.56 Hz, 1H),
4.01 (dd, J= 12.06, 3.13 Hz, 1H), 3.02 (m, 1H), 2.58 (m, 2H), 1.91 (m, 2H), 1.70 (s, 3H),
1.63 (s, 3H), 1.31 (s, 9H), 1.30 (m, 1H)
‘3C-NMR (400 MHz, CDC13): 6 163.9, 140.8, 131.1, 129.9, 128.3, 127.8, 127.5, 125.9, 61.4,
1 -(4-tert-Butyl-benzenesulfonyl)-5R-(1-methyl-1 -nîtro-ethyl)-2R-phenyl-piperidîne
6$
46.7, 44.1, 32.6. 31.5, 24.3, 23.6, 23.4
MS (M+1): 445.1, 398.2, 356.1, 307.1, 289.0, 247.1, 200.1, 173.1, 154.0, 136.0, 117.0
HRMS: C24H33N204S (M+1); Calcd.: 445.2156; found: 445.2161
I,,
5R-(1 -Methyl-1 -nitro-ethyl)-2R-phenyl-1-(3-trifluoromethyl-benzenesulfonyl)piperidine
(2.48b)
According to general procedure A, starting from 2.33 to give 2.4$b (23 mg, 81%)
1 NMR (400 IVifiz, CDC13): 7.62 (d, J= 7.51 Hz, 2H), 7.53 (d, 1= 7.80 Hz, 2H), 7.39 (m,
2H), 7.10 (m, 1H), 7.09 (m, 4H), 4.31 (dd, J= 9.71, 6.13 Hz, 1H), 4.08 (dd, J 12.65, 4.71
Hz, 1H), 3.18 (dd, J= 12.78, 8.36 Hz 1H), 2.62 (m, 1H), 1.99 (m, 2H), 1.82 (m, 1H), 1.73 (s,
3H), 1.66 (s, 3h), 1.41 (m, 1H)
‘3C-NMR (400 MHz, CDC13): 142.2, 138.7, 130.8, 129.6, 129.1, 128.8, 128.6, 128.4,
127.5, 124.5, 91.1, 62.3, 46.8, 44.4, 32.2, 24.2, 24.1, 23.5
1 -(4-Chloro-benzenesulfonyl)-5R-(1-methyl-1 -nitro-ethyl)-2R-phenyl-piperidine (2.48c)
cl
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According to general procedure A, starting from 2.33 to give 2..48c (25 mg, 81%)
‘H NMR (400 IVfHz, CDCÏ3): 7.21 (m, 5H), 7.09 (m, 4H), 4.28 (dd, J 9.94, 5.23 Hz, 1H),
3.99 (dd, J= 12.64, 4.79 Hz, 1H), 2.58 (m, 1HO, 1.94 (m, 1H), 1.72 (m, 1H), 1.70 (s, 3H),
1.64 (s, 3H), 1.39 (m, 1H)
‘3C-NMR (400 MHz, CDC13): 161.9, 140.2, 131.0, 129.1, 128.9, 128.6, 128.4, 128.2, 91.3,
61.9, 45.5, 44.2, 32.5, 24.0, 23.8, 23.6,
1I
5R-(1-Methyl-1-nïtro-ethyl)-2R-phenyl-1-(toluene-4-sulfonyl)-piperidine (2.48d)
According to general procedure A, starting from 2.33 to give 2.48d (24 mg, 81%)
‘H NMR (400 MHz, CDC13): 7.31 (d, J= 8.84 Hz, 2H), 7.15 (m, 5H), 6.77 (d, J= 8.84 Hz,
2H), 4.18 (dd, J= 9.71, 6.13 Hz, 1H), 4.08 (dd, J= 9.04, 5.47 Hz, 1H), 3.95 (dd, J= 12.17,
4.29 Hz 1H), 3.83 (s, 3H), 2.88 (m, 1H), 2.52 (m, 1H), 1.90 (m, 2H), 1.68 (m, 1H), 1.67 (s,
3H), 1.61 (s, 3H), 1.39 (m, 1H).
‘3C-NMR (400 MHz, CDC13): 143.1, 140.3, 136.7, 129.5, 128.7, 128.4, 128.1, 127.9, 91.3,
61.6, 46.6, 43.8, 32.9, 23.7, 22.4, 21.6.
MS (M+1): 403.1, 356.1, 307.1, 289.0, 247.1, 200.1, 184.1, 173.1, 154.1, 136.0, 117.0.
HRMS: C21H27N204$ (M+1); Calcd.: 403.1696; found: 403.1692.
H3
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1 -(4-Methoxy-benzenesulfonyl)-5R-(1-methyl-1-nitro-ethyl)-2R-phenyl-piperidine
(2.48e)
According to general procedure A, starting from 2.33 to give 2.48e (27 mg, 79%)
‘11 NN’IR (400 MHz, CDC13): 7.31 (d, Jrz 8.93 Hz, 2H), 7.15 (m, 5H), 6.77 (d, J= 8.92 Hz,
2H), 4.1$ (dd, J= 9.20, 5.56 Hz, 1H), 3.98 (dd, J= 12.06, 3.13 Hz, 1H), 3.84 (s, 3H), 2.8$
(dd, J 12.15, 9.34 Hz, 1H), 2.52 (m, 1H), 1.90 (m, 2H), 1.6$ (m, 1H), 1.61 (s, 3H), 1.39 (m,
1H).
13C-NMR (400 MHz, CDC13): 163.9, 140.8, 131.1, 129.9, 128.4, 128.2, 127.1, 91.0, 61.5,
56.0, 46.6, 44.0, 32.8, 24.3, 23.6, 23.5.
MS (M+1): 419.1, 372.1, 307.1, 289.0, 200.0, 171.0, 154.1, 136.0, 123.0.
HRMS: C21H27N705S (M+1); Calcd.: 419.1641; found.: 419.163$.
(3R)-1 -[1 -(4-tert-Butyl-benzenesulfouyl)-6R-phenyl-piperidiu-3-ylJ
-1 -methyl-ethylamine
(2.49a)
According to general procedure C, starting from 2.48a to give 2.49a (25 mg, 82%).
N H2
71
1H NMR (400 MHz, CDCI3): 7.37 (d, J= 8.46 Hz, 2H), 7.30 (d, J 8.48 Hz, 2H), 7.17-
0 7.11 (m, 5H), 4.26 (m, 1H), 4.05 (m, 1H), 2.30 (mk, 1H), 1.88 (m, 2H), 1.76 (m, 2H), 1.50
(br, 2H), 1.31 (s, 9H), 1.30 (m, 1H), 1.16 (s, 3H), 1.13 (s, 3H).
13C-NMR (400 MHz, CDCI3): 160.0, 141.6, 136.4, 128.2, 128.1, 127.6, 126.4, 125.9, 61.1,
46.7, 46.2, 35.4, 233.1, 3 1.5, 29.2, 28.4, 23.0.
MS (M+1): 415.2, 398.2, 307.1, 289.1, 226.1, 154.0, 136.0, 116.9.
HRMS: C24H34N202S (M+1); Calcd.: 415.2419; found: 415.2419.
‘I,,
(3R-1-Methyl-1 - [6R-phenyl-1-(3-trifluoromethyl-benzenesulfonyl)-piperïdin-3-yIJ ethyl
amine (2.49b)
According to general procedure C, starting from 2.4$b to give 2.49b (15 mg, 75%).
1H NMR (400 MHz, CDC13): 7.62 (d, J= 7.51 Hz, 2H), 7.53 (d, J 7.80 Hz, 2H), 7.39 (m,
2H), 7.10 (m, 1H), 7.09 (m, 4H), 4.31 (dd, J= 9.71, 6.13 Hz, 1H), 4.08 (dd, J= 12.65, 4.71
Hz, 1H), 3.18 (dd, J= 12.78, 8.36 Hz 1H), 2.62 (m, 1H), 1.99 (m, 2H), 1.82 (m, 1H), 1.73 (s,
3H), 1.66 (s, 3h), 1.41 (m, 1H).
13C-NMR (400 MHz, CDCÏ3): 161.3, 142.2, 138.7, 132.1, 129.58, 128.79, 128.57, 128.36,
91.14, 62.29, 46.76, 44.39, 32.25, 32.25, 24.17, 24.10, 23.52.
MS (M+1): 427.1, 238.0, 173.1, 136.0, 116.9.
HRMS: C2H26f3N2O2S (M+1); Calcd.: 427.1654; found: 427.1667.
3
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3R-1-tl-(4-Chloro-henzenesulfonyl)-6R-phenyl-pïperidin-3-yIl-1-methyl-ethylamine
(2.49c)
According to general procedure C, starting from 2.48c to give 2.49c (1$ mg, 77%).
‘H NMR (400 MHz, CDCI3): 6 7.47 (d, J 7.86 Hz, 2H), 7.34 (d, J= 7.50 Hz, 2H), 7.20 (m,
5H), 4.27 (dd, J= 14.1, 7.09 Hz, 1H), 4.02 (dd, J= 14.0, 7.68 Hz, 1H), 2.96 (dd, J 11.8,
9.31 Hz, 1H), 1.8$ (m, 2H), 1.76 (m, 2H), 1.56 (br, 2H), 1.31 (m, 1H), 1.15 (s, 3H), 1.13 (s,
3H).
MS (M+1): 393.1, 307.1, 289.0, 154.0, 137.0, 119.9.
HRMS: C20H26C1N202S (M+1); Calcd.: 393.1404; found: 393.1394.
3R-1 -Metliyl-1 - j6R-phenyl-1 -(toluene-4-sulfonyl)-piperidin-3-yl]-ethylamïne, 2.49d
According to general procedure C, starting from 2.48d to give 2.49d (1 8mg, 76%).
‘H NMR (400 MHz, CDC13): 6 7.31 (d, J= 8.84 Hz, 2H), 7.15 (m, 5H), 6.77 (U, J 8.84 Hz,
2H), 4.18 (dU, J= 9.71, 6.13 Hz, 1H), 4.08 (dd, J= 9.04, 5.47 Hz, 1H), 3.95 (dd, J= 12.17,
N H2
73
4.29 Hz 1H), 3.83 (s, 3H), 2.88 (m, 1H), 2.52 (m, 1H), 1.90 (m, 2H), 1.68 (m, 1H), 1.67 (s,
3H), 1.61 (s, 3H), 1.39 (m, 1H).
HRMS: C21H29C1N202$ (M+1); Calcd.: 373.5248; found: 373.52463.
31t-1 -[1 -(4-Methoxy-benzenesulfonyl)-6R-phenyl-piperidin-3-ylj-1-methyl-ethylamîne,
2.49e
According to general procedure C, starting from 2.48e to give 2.49e (19 mg, 78%).
1fl NMR (400 IVII{z, CDC13): 7.31 (d, J= 8.93 Hz, 2H), 7.15 (m, 5H), 6.77 (d, J= 8.92 Hz,
2H), 4.18 (dd, J= 9.20, 5.56 Hz, 1H), 3.98 (dd, J= 12.06, 3.13 Hz, 1H), 3.84 (s, 3H), 2.88
(dd, J= 12.15, 9.34 Hz, 1H), 2.52 (m, 1H), 1.90 (m, 2H), 1.68 (m, 1H), 1.61 (s, 3H), 1.39 (m,
1H).
13C-NMR (400 MHz, CDCY3): 162.8, 141.9, 130.8, 130.0, 128.3, 127.9, 127.6, 114.1, 61.1,
55.9, 52.0, 46.9, 46.0, 33.2, 29.1. 28.3, 23.1.
MS (M+1): 389.2, 307.1, 200.0, 154.0, 132.8, 116.9.
HR1’slS: C71H29N203S (M+1); Calcd.: 389.1896; found: 389.1899.
q\,JJ
‘,NHBoc
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3R- { 1- [1 -(4-tert-Butyl-benzenesulfonyl)-piperidin-3-ylj-1-methyl-ethyl}-carbamic acid
tert-butyl ester (2.50a)
According to general procedure A, starting from 2.39 to give 2.50a (25 mg, 82%).
‘H NMR (400 MHz, CDC13): 7.70 (d, J= 8.41 Hz, 2H), 7.52 (d, J= 8.41 Hz, 2H), 4.01 (m,
1H), 3.79 (m, 1H), 2.4 (s, 2H), 2.13 (m, 1H), 2.03 (m, 1H), 1.88 (m, 1H), 1.77 (m, 1H), 1.61
(m, 2H), 1.13 (s, 3H), 1.11 (s, 3H), 0.98 (m, 1H).
13C-NMR (400 MHz, CDC13): 163.33, 130.14, 128.71, 114.52, 55.97, 54.45, 48.20, 46.85,
43.93, 28.83, 25.58, 25.50, 25.33.
NHBoc
3R-{ 1 -Methyl-1 -[1 -(3-trifluoromethyl-beuzenesulfonyl)-piperidin-3-yl]-ethyl}-carbamic
acid tert-butyl ester (2.50b)
According to generaÏ procedure A, starting from 2.39 to give 2.50b (25 mg, 82%).
NMR (400 MHz, CDCY3): 8.03 (s, 1H), 8.0 (d, J= 7.89 Hz,1H), 7.86 (d, J 7.89 Hz,
2H), 7.70 (d, J= 7.82, 7.87 Hz, 1H), 4.05 (m, 1H), 3.84 (m, 1H), 2.45 (s, 2H), 2.17 (m, 1H),
2.08 (m, 1H), 1.90 (m, 1H), 1.82 (m, 1H), 1.60 (m, 2H), 1.38 (s, 9H), 1.13 (s, 3H), 1.10 (s,
3H), 0.99 (m, 1H).
13C..NMR (400 MHz, CDC13): 139.0, 13 1.2, 130.3, 129.65, 124.9, 48.1, 79.8, 46.9, 46.7,
28.8, 28.1, 25.4, 25.2.
75
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3R-{1 -[1-(4-Chtoro-benzenesulfonyl)-pïperidin-3-yl] -1-methyl-ethyl}-carbamic acid tert
butyl ester (2.50c)
According to general procedure A, starting from 2.39 to give 2.50c (25 mg, 82%)
‘H NMR (400 MHz, CDC13): 7.68 (d, J= 7.96 Hz,IH), 7.55 (d, J= 7.89 Hz, 2H), 4.02 (m,
1H), 3.78 (m, 1H), 3.78 (s, 2H), 3.78 (brs, 2H), 2.02 (m, 2H), 1.89 (m, 1H), 1.80 (m, 1H),
1.64 (m, 2H), 1.82 (m, 1H), 1.39 (s, 9H), 1.17 (s, 3H), 1.14 (s, 3H), 0.99 (m, 1H)
MS (M+1): 417.1, 361.1, 343.1, 300.1, 241.2, 154.0, 136.0, 120.0
HRMS: C19H29C1N204S (M+1); Calcd.: 417.1615; found: 417.1598
N HBoc
3R-{1 -Methyl-1
- ti -(toluene-4-sulfonyl)-pïperidin-3-ylJ -ethyl}-carbamic acid tert-butyl
ester (2.50d)
According to general procedure A, starting from 2.39 to give 2.50d (25 mg, 82%).
‘H NMR (400 MHz, CDCY3): 7.61 (d, J= 8.0 Hz, 2H), 7.21 (d, J 7.84 Hz, 2H), 3.89 (m,
1H), 3.81 (rn, 1H), 3.4-2.8 (s, 2H), 2.43 (s, 3H), 2.09 (dd, J 12.0, 9.39, Hz, 1H), 1.99 (m,
1H), 1.87 (m, 1H), 1.78 (m, 1H), 1.59 (m, 2H), 1.37 (s, 9H), 1.12 (s, 3H), 1.11 (s, 3H), 0.96
(m, 1H).
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‘3C-NMR (400 MHz, CDC13): 143.8, 133.7, 130.1, 128.1, 51.5, 80.8, 48.7. 46.9, 46.6,
28.4, 27.9, 25.4, 25.2, 2 1.2.
MS (M+1): 397.2, 341.1, 307.1, 280.1, 241.2, 154.0, 136.0, 123.0.
HRMS: C20H32N204S (M+1); Calcd.: 397.2161; found: 397.2160.
OCH3
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3R-{ 1- [1 -(4-Methoxy-benzenesulfonyl)-piperidin-3-yll-1-methyl-ethyl}-carbamic acid
tert-butyl ester (2.50e)
According to general procedure A, starting from 2.39 to give 2.50e (25 mg, 82%)
‘H NMR (400 MHz, CDC13): 7.61 (d, J= 8.87 Hz, 2H), 7.0 (d, J 8.90 Hz, 2H), 4.04 (m,
1H), 3.87 (s, 3H), 3.76 (m, 1H), 2.03 (m, 2H), 1.84 (m, 1H), 1.78 (m, 1H), 1.62 (m, 1H), 1.38
(s, 9H), 1.25 (s, 3H), 1.23 (s, 1H), 0.98 (m, 1H).
‘3C-NMR (400 MHz, CDC13): 163.28, 130.23, 128.21, 114.62, 56.0, 48.09, 46.88, 44.0,
25.26, 25.22.
MS (M+1): 413.1, 357.1, 339.1, 313.1, 296.1, 289.1, 241. 214.0, 185.1, 171.0, 154.1, 136..0,
124.1.
HR1VIS: C20H33N205S (M+1); Calcd.: 413.2110; found: 413.2101.
3R-1 -[1 -(4-tert-Butyl-benzenesulfonyl)-piperidin-3-ylj-1-methyl-ethylamine (2.51 a)
77
According to general procedure A, starting from 2.50a to give 2.51a (25 mg, 82%).
1H NMR (400 MHz, CDC13): 7.70 (d, J= 8.41 Hz, 2H), 7.52 (d, J= 8.41 Hz, 2H), 4.01
(m, 1H), 3.79 (m, 1H), 2.4 (s, 2H), 2.13 (m, 1H), 2.03 (m, 1H), 1.8$ (m, 1H), 1.77 (m, 1H),
1.61 (m, 2H), 1.35 (s, 9H), 1.13 (s, 3H), 1.11 (s, 3H), 0.98 (m, 1H).
‘3C-NMR (400 MHz, CDC13): 163.3, 130.1, 128.7, 114.5, 56.0, 55.9, 54.5, 48.2, 46.9,
43.9, 28.8, 25.6, 25.5, 25.3.
163.33, 130.14, 128.71, 114.52, 86.02, 55.97, 54.45, 48.20, 46.85, 43.93, 28.83, 25.58, 25.50,
25.33.
MS (M+1): 339.2, 322.2, 307.1, 289.1, 154.0, 136.0, 124.0.
HRMS: C18H31N207S (M+1); Calcd.: 339.2124; found: 339.2106.
0V°CF3
NH
3R-1-Methyl-1
- [1-(3-trifluorometliyl-benzenesulfonyl)-pïperidin-3-yI]-ethylamine, 2.51 b
According to general procedure D, starting from 2.50b to give 2.51b (25 mg, 82%).
‘II NMR (400 MHz, CDC13): (5 8.03 (s, 1H), 8.0 (d, J= 7.89 Hz,1H), 7.86 (d, Jz= 7.89 Hz,
2H), 7.70 (d, J= 7.82, 7.87 Hz, 1H), 4.05 (m, 1H), 3.84 (m, 1H), 2.45 (s, 2H), 2.17 (m, 1H),
2.08 (m, 1H), 1.90 (m, 1H), 1.82 (m, 1H), 1.60 (m, 2H), 1.13 (s, 3H), 1.10 (s, 3H), 0.99 (m,
1H).
‘3C-NMR (400 MHz, CDC13): (5 165.1, 139.0, 13 1.2, 130.3, 129.6, 124.9, 52.1, 48.1, 46.9,
46.7, 28.8, 28.1, 25.4, 25.2.
MS (Mj: 350.1, 338.2.
IIRMS: C15H21F3N202S (M); Calcd: 350.1276; found: 350.1282.
78
NH
3R-{1 -[1 -(4-Chloro-benzenesulfonyl)-piperïdïn-3-yl]-1-methyl-ethylamïne (2.51 c)
According to general procedure D, starting from 2.50c to give 2.51c (25 mg, 82%).
1H NMR (400 MHz, CDC13): 7.68 (d, J= 7.96 Hz,1H), 7.55 (d, J= 7.89 Hz, 2H), 4.02 (m,
1H), 3.78 (m, 1H), 3.78 (s, 2H), 3.78 (brs, 2H), 2.02 (m, 2H), 1.89 (m, 1H), 1.80 (m, 1H),
1.64 (m, 2H), 1.82 (m, 1H), 1.17 (s, 3H), 1.14 (s, 3H), 0.99 (m, 1H).
MS (M+l): 3 17.1, 307.1, 289.1, 54.0, 136.0.
HRMS: C14H21C1N202S (M+1); Calcd.: 317.1091; found: 317.1090.
CNH2
3R-{ 1 -Methyl-1 -[i-(toluene-4-sulfonyl)-piperidin-3-yIJ-ethylamine (2.51 d)
According to general procedure D, starting from 2.50d to give 2.51d (25 mg, 82%).
‘H NMR (400 MHz, CDCI3): 7.66 (d, J= 8.10 Hz, 2H), 7.32 (d, J 7.92 Hz, 2H), 3.98 (m,
1H), 3.78 (m, 1H), 3.4-2.2 (s, 2H), 2.43 (s, 3H), 2.09 (dd, J= 12.0, 9.39, Hz, 1H), 1.99 (m,
1H), 1.87 (m, 1H), 1.78 (m, 1H), 1.59 (m, 2H), 1.12 (s, 3H), 1.11 (s, 3H), 0.96 (m, 1H).
13C-NMR (400 MHz, CDCI3): 143.8, 133.7, 130.1, 128.1, 51.5, 48.1, 46.9, 46.6, 28.4,
28.0, 25.4, 25.2, 21.9.
HRMS: C15H24N202S (M); Calcd: 296.1559; found: 296.1569.
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3R-1 -[1 -(4-Methoxy-benzenesulfonyl)-piperïdin-3-yl]-1-methyl-ethylamine (2.51 e)
According to general procedure D, starting from 2.50e to give 2.51e (25 mg, 82%).
1H NMR (400 MHz, CDC13): 7.76 (d, J= 8.87 Hz, 2H), 7.35 (d, J 8.90 Hz, 2H), 4.04
(m, 1H), 3.85 8 (m, 1H), 3.4-2.8 (s, 2H), 2.43 (s, 3H), 2.09 (dd, J 12.0, 2.3, Hz, 1H), 1.99
(m, 1H), 1.87 (m, 1H), 1.78 (m, 1H), 1.59 (m, 2H), 1.12 (s, 3H), 1.11 (s, 3H), 0.96 (m, 1H).
13C-NMR (400 Mhz, CDC13): 16.2, 130.2, 122.2, 114.6, 56.0, 48.1, 46.9, 45.7, 29.3, 28.7,
25.3, 25.2, 21.2.
MS (M+1): 313.1, 296.1, 214.0, 171.1, 132.8, 124.0.
HRMS: C15H24N203S (M+1); Calcd.: 312.1508; found: 312.1504.
3R- [1 -(4-tert-BntyI-benzoylamino)-1 -methyl-ethylJ-piperidine-1-carboxylic acïd tert
butyl ester (2.521)
According to general procedure B, starting from 2.42 to give 2.52f (27 mg, 81%).
‘II NMR (400 MHz, CDC13): 6 7.65 (d, J= 8.15, 2H), 7.25 (d, J 8.18, 2H), 5.88 (s, 1H),
4.25 (s, 2H), 4.05 (m, 1H), 2.94 (m, 1H), 2.53(m, 2H), 2.30 (m, 1H), 1.95 (m, 1H), 1.67 ((m,
1H), 1.45 (s, 6H), 1.40 (s, 9H), 1.24 (s, 9H), 1.20 (m, 1H).
‘3C-NMR (400 MHz, CDCÏ3): 6 169.36, 155.86, 134.14, 128.2, 126.21, 59.02, 46.83, 43.12,
35.63, 3 1.57, 26.59, 26.3 8, 24.64, 24.64.
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HRMS: C74H38N203 (M+1); Calcd.: 402.2882; found: 402.2887.o
butyl ester (2.52g)
According to general procedure B, starting from 2.42 to give 252g (25 mg, 82%)
‘H NMR (400 MHz, CDCI3): 8 7.70 (d, J= 7.99 Hz, 2H), 7.30 (d, J 8.26 Hz, 2H), 4.19 (m,
1H), 4.05 (S, 1H), 2.95 (m, 1H), 2.59-2.32 (m, 3H), 1.87 (m, 1H), 1.1.72 (m, 1H)
‘3C-NMR (400 MHz, CDC13): 6
HRMS: C23H36N203 (M+1); Calcd.: 388.2726; found: 388.2729
dine-1-carboxylic acid tert-butyl ester (2.52 h)
According to general procedure B, starting from 2.42 to give 2.52h (25 mg, 81%)
‘H NMR (400 MHz, CDC13): 6 7.66 (d, J= 8.48, 2H), 7.31 (d, J 8.12, 2H), 5.90 (s, 1H),
4.95 (m, 1H), 4.76 (m, 1H), 4.11, (m, 2H), 2.50 (m, 2H), 2.22 (rn, 1H), 1.87 (m, 1H), 1.67
(m, 1H), 1.42 (s, 3H), 1.39 (m, 22H), 1.20 (m, 2H), 3H), 1.14 (s, 3H), 1.29 (m, 2H)
‘3C-NMR (400 MHz, CDCI3): 6 166.98, 155.42, 155.19, 148.12, 134.87, 127.45, 126.29,
79.97, 79.77m 66.25 (60.8 1), 56.21 (50.39), 44.36 (43.55), 28.8, 26.2, 25.85, 24.98, 24.75,
23.11, 15.67 (14.61)
MS (M+1): 490.1, 434.2, 388.2, 334.2, 307.1, 209.1, 192.1, 154.0, 136.0
3R- [1-(4-Isopropyl-benzoylamino)-1 -methyl-ethyl]-piperidine-1-carboxylic acid tert
3R-{ 1- [4-(1S-tert-Butoxycarbonylamïno-ethyl)-benzoylamino]-1-methyl-ethyl}-piperi-
$1
HRMS: C27H44N305 (M+1); Calcd.: 490.3281; found: 490.3295ç
Bac
3R-{1- j(trans-4-Isopropyl-cyclohexanecarbonyl)-amino]-1-methyl-ethyl}-piperîdine-1
-
carboxylïc acid tert-butyl ester (2.52i)
According ta general procedure B, starting from 2.42 to give 2.52i (21 mg, 82%)
1H NMR (400 MHz, CDC13): 5.23 (m, 1H), 4.10 (m, 2H), 2.55 (m, 1H), 2.43 (m, 1H),
2.19-2.1.89 (M, 7H), 1.80 (m, 1H), 1.68 (m, 1H), 1.54 (m, 3H), 1.43 (s, 9H), 1.35 (m, 2H),
1.31 (s, 3H), 1.2$ (s, 3H), 1.16 (m, 1H),
‘3C-NMR (400 MHz, CDC13): 175.97, 155.24, 79.74, 55.35, 46.96, 43.61, 43.45, 33.17,
30.41, 30.32, 29.39, 28.86, 26.04, 25.81, 25.01, 24.74, 20.14
HRMS: C23H42N203 (M+1); Calcd.: 394.3195; found: 394.3191
CF3
3R-{ 1 -Methyl-1
- ((trans-4-trifluoromethyl-cyclohexanecarbonyl)-aminoj-ethyl}-piperid-
me-1 -carboxylic acid tert-butyl ester (2.52j)
According ta general procedure B, starting from 2.42 ta give 2.52j (23 mg, 81%)
‘H NMR (400 MHz, CDCI3): 5.23 (m, 1H), 4.10 (m, 2H), 2.55 (m, 1H), 2.43 (m, 1H),
2.19-2.1.89 (M, 7H), 1.80 (m, 1H), 1.6$ (m, 1H), 1.54 (m, 3H), 1.43 (s, 9H), 1.35 (m, 2H),
1.31 (s, 3H), 1.2$ (s, 3H), 1.16 (m, 1H),
‘3C-NMR (400 MHz, CDC13): 174.71, 155.25, 79.81, 55.85, 55.64, 45.7343.55, 41.68,
41.42, 28.86, 28.52, 28.45, 26.05, 25.82, 25.03, 24.95, 24.61, 23.99
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HRrVIS: C21H35F2N203 (M+1); Calcd.: 420.5094; found: 420.5089
e
31?- ti -Metliyl-1 -(4-trifluoromethyl-beuzoylamino)-ethyl]-pïperidïne-1 -carboxylïc acid
tert-butyl ester (2.52k)
According to general procedure B, starting from 2.42 to give 2.52k (24 mg, 84%)
‘H NMR (400 MHz, CDC13): 6 7.79 (d, J= 7.76 2H), 7.67 (d, J= 7.88, 2H), 6.07 (s, 1H),
4.20 (s, 1H), 4.07 (m, 1H), 2.55 (m, 2H), 2.22 (m, 1H), 1.87 (m, 1H), 1.72 (m, 1H), 1.46 (s,
3H), 1.43 (s, 3H), 1.41 (s, 9H), 1.23 (m, 2H)
‘3C-NMR (400 MHz, CDCÏ3): 6 165.97, 155.23, 139.44, 127.63, 126.02, 125.97,
125.92,79.9, 56.7, 43.62, 28.8, 26.19, 25.83, 24.98, 24.5
MS (M+1): 415.2, 359.1, 341.1, 31501, 231.1, 190.1, 168.1, 154.0, 136.0, 124.1
HRMS: C21H28F3N203 (M+1); Calcd.: 415.2052; found: 415.2040
31?- [1-(4-tert-Butyl-benzenesulfonylamino)-1-methyl-ethyl] -piperidine-1 -carboxylic acid
tert-butyl ester (2.551)
According to general procedure A, starting from 2.42 to give 2.551 (23 mg, 79%)
TI NMR (400 MHz, CDC13): 6 7.81 (d, J= 8.27, 2H), 7.46 (d, J= 8.49, 2H), 4.76 (s, 1H),
4.18 (s, 1H), 4.05 (m, 1H), 2.50 (m, 1H), 2.37, 1.87 (m, 2H), 1.64 ((m, 1H), 1.53 (m, 1H),
1.46 (s, 9H), 1.33 (s, 9H), 1.19 (s, 3H), 1.15 (s, 3H),
83
13C-NMR (400 IVifiz, CDCI3): 6 156.31, 155.22, 140.87, 127.07, 126.29, 79.84, 79.74, 59.76,
58.78, 46.59, 35.48, 3 1.48, 28.84, 27.02, 25.74, 25.06
MS (M+1): 439.2, 323.2, 365.2, 339.2, 307.1, 289.0, 254.1, 197.1, 170.1, 154.0, 136.0, 126.1
HRMS: C23H39N204S (M+1); Calcd.: 439.2631; found: 439.2641
Soc
3R-[1 -(4-Acetyl-benzenesulfonylamino)-1-methyl-ethylJ-piperidine-1-carboxylic acid
tert-butyl ester (2.55m)
According to general procedure A, starting from 2.42 to give 2.55m (11 mg, 81%)
‘H NMR (400 MHz, CDC13): 6 8.03 (d, J= 8.48, 2H), 7.97 (d, 1= 8.52, 2H), 5.42 (s, 1H),
2.64 (s, 3H), 2.52 (m, 1H), 2.36 (m, 1H), 1.87 (m, 1H), 1.60 (m, 2H), 1.16 (s, 3H), 1.14 (s,
3H), 1.29 (m, 2H)
13C-NMR (400 MHz, CDC13): 6 197.33, 155.19, 155.0 147.87, 139.96, 129.29, 127.52,
79.93, 79.84, 60.17, 59.29, 46.57, 28.82, 27.3, 26.95, 25.7, 25.17, 25.02
MS (M+1): 425.1, 369.1, 351.1, 325.1, 240.0, 170.1, 154.0, 126.1
HRMS: C21H33N205S (M+1); Calcd.: 425.2110; found: 425.2106
H
HCI
4-tert-Butyl-N-(1 -methyl-1-piperïdin-3R-yl-ethyl)-benzamide hydrochioride (2.541)
According to general procedure D and E, starting from 2.52f to give 2.54f (11 mg, 84%)
1H NMR (400 MHz, CD3OD): 6 7.68 (d, J= 8.45, 2H), 7.48 (d, J 8.50, 2H), 3.17 (in, 1H),
3.07 (m, 1H), 2.57 (m, 2H), 1.85 (m, 2H), 1.56 (m, 11.33 (m, 1H)
84
e
13C-NMR (400 IvfHz, CD3OD): 169.36, 154.96, 133.14, 127.14, 125.34, 56.02, 45.59,
42.65, 34.73, 30.56, 25.49, 25.38, 23.7, 23.59
HRMS: C19H30N20 (M+1); Calcd.: 302.2358; found: 302.2354
4-Isopropyl-N-(1-methyl-1-piperidïn-3R-yl-ethyl)-benzamide hydrochioride (2.54g)
According to general procedure D and E, starting from 2.52g to give 2.54g (17 mg, 81%)
‘H NMR (400 MHz, CD3OD): 6 7.87 (d, J= 7.83 Hz, 2H), 7.63 (d, J= 7.90 Hz, 2H), 6.21 (s,
1H), 3.49 (m, 1H), 3.31 (m, 1H), 2.89 (m, 3H), 1.88 (m, 1H), 1.43 (s, 3H), 1.3$ (s, 3H), 1.24
(d, J — 6.35 Hz, 6H). 1.20 (m, 2H)
13C-NMR (400 MHz, CD3OD): 6 167.92, 153.23, 132.99, 127.44, 127.07, 66.29, 55.88,
45.93, 44.18, 41.51, 34.46, 25.25, 24.59, 24.45, 24.19, 23.09. 15.69
MS: (M+1) 289.2, 206.1, 125.1, 84.1
HRMS: C18H29N20 (M+1); Calcd.: 289.22154; found: 289.2156
HCI
4-(1$-Amino-ethyl)-N-(1-methyl-1-piperïdin-3R-yl-ethyl)-benzamîde
(2.54h)
hydrochioride
According to general procedure D and E, starting from 2.52h to give 2.54h (9 mg, 81%)
‘H NMR (400 MHz, CD3OD): 6 7.72 (d, J= 8.32 Hz, 2H), 7.44 (d, J 8.15, 2H), 4.09 (q, J
= 6.60 Hz, 1H), 3.12 (m, 1H), 3.20 (m, 1H), 2.51 (m, 3H), 1.83 (m, 2H), 1.53 (m, 1H), 1.39
(m. 9H), 1.1.33 (m, 1H)
85
13C-NMR (400 MFIz, CD3OD): 6 167.92, 153.23, 132.99, 127.44, 127.07, 66.29, 55.88,
0 45.93, 44.18, 41.51, 34.46, 25.25, 24.59, 24.45, 24.19, 23.09. 15.69
MS (M+1): 289.2, 206.1, 125.1, 84.1
HRMS: C17H27N30 (M+1); Calcd.: 289.2154; found: 289.2156
H
HCI
trans-4-Isopropyl-cyclohexanecarboxylic acid (1 -methyl-1 -piperidïn-3R-yl-ethyl)-amide
hydrochioride (2.54i)
According to general procedure D and E, starting from 2.52i to give 2.54i (13 mg, 82%)
‘H NMR (400 MHz, CD3OD): 6 3.0 (m, 2H), 2.42 (m, 2H), 2.25 (m, 1H), 2.1 (m, 1H), 1.76
(m, 6H), 1.45 (m, 4H), 1.25 (m, 7H), 1.12 (m, 3H), 0.88 (d, J = 6.78 Hz 6H)
‘3C-NMR (400 MHz, CD3OD): 6 177.69, 55.09, 46.0, 43.81, 43.37, 33.11, 29.97, 29.16,
26.39, 25.73, 23.74, 23.61, 19.15
MS (M): 294.3, 211.2, 125.1, 98.1
HRMS: C18H34N20 (M); Calcd.: 294.2671; found: 294.2678
HCI
trans-4-(Trifluoromethyl)cyclohexanecarboxylic acid (1 -methyl-1 -piperidin-3R-yl-
ethyl)amïde hydrochioride (2.54j)
According to general procedure D and E, starting from 2.42j to give 2.54j (15 mg, 83%)
‘H NMR (400 MHz, CD3OD): 6 3.31 (m, 1H), 3.04 (m, 2H), 2.47 (m, 2H), 2.27 (m,. 1H),
2.15 (m, 2H0, 1.98 (m, 2H), 1.84 (m, 4H), 1.49 (m, 3H), 1.38-1.30 (m, 6H), 1.26 (s, 6H)
86
o 13C-NMR (400 IVifiz, CD3OD): 6 166.59, 55.14, 45.79, 44.72, 43.02, 41.47, 41.21, 28.08,25.92, 25.48, 24.35, 23.59
MS (M): 320.2, 318.2, 236.1, 125.1, 84.1
HRMS: C16H27f3N20 (Mj: Calcd.: 320.2075; found: 320. 2083
HCI
N-(1 -Methyl-1 -piperidin-3R-yI-ethyl)-4-trifluoromethyl-benzamide
(2.54k)
hydrochioride,
According to general procedure D and E, starting from 2.52k to give 2.54k (15 mg, 83%)
‘H NMR (400 MHz, CD3OD): 6 7.87 (d, J= 8.12, 2H), 7.65 (d, J= 8.2$ Hz, 2H), 3.12 (m,
1H), 3.01 (m, 1H), 2.48 (m, 3H), 1.83 (m, 2H), 1.53 (m, 1H), 1.45 (5, 3H), 1.40 (s, 3H). 1.32
(m, 1H),
13C-NMR (400 MHz, CD3OD): 6 168.45, 138.90, 128.04, 127.73, 125.85, 56.33, 45.95,
44.60, 44.118, 41.78, 25.18, 24.72, 24.48, 23.69, 23.09
HRMS: Ci6H2iF3N2O(M); Calcd.: 314.1612; found: 314.1607
4-tert-Butyl-N-(1 -methyl-1 -piperidin-3R-yl-ethyl)-beuzenesulfonamïde hydrochlorïde
(2.571)
According to general procedure D and E, starting from 2.551 to give 2.571 (18 mg, 86%)
‘H NMR (400 MHz, CD3OD): 6 3.14 (m, 2H), 2.47 (m, 2H), 2.26 (m, 1H), 2.14 (m, 1H),
1.99 (m, 2H), 1.82 (m, 4H), 1.49 (m, 3H), 31.38-1.26 (m, 9H)
HCI
$7
13C-NMR (400 MHz, CD3OD): 166.59, 55.14, 45.79, 44.72, 43.02, 41.47, 28.08, 25.92,
0 25.48, 24.35, 23.59
HRMS: C18H31N702 S (IvJ+1); Calcd.: 339.2104; found: 339.2101
ester (2.5$g)
According to general procedure B, starting from 2.45 to give 2.58g (24 mg, 81%)
‘H NMR (400 MHz, CDCI3): 7.63 (d, J= 8.26, 2H), 7.24 (d, J 8.15, 2H), 5.87 (s, 1H),
4.13 (m, 1H), 2.91 (m, 1H), 2.64 (m, 2H), 2.43 (m, 2H), 1.65 (m, 2H),
‘3C-NMR (400 MEz, CDC13): 167.15, 155.13, 152.89, 133.57, 127.19, 127.0, 79.79, 56.85,
44.54, 42.75, 34.44, 34.44, 28.86, 27.26, 24.86, 24.20
HRMS: C73H35N703 (M-1); Calcd.: 387.2648; found: 387.2637
BocNQ
4-[ 1 -Methyl- 1 -(4-trifluoromethyl-benzoylamino)-ethyl] -piperidine- 1 -carboxylic acid tert
butyl ester (2.58k)
According to general procedure B, starting from 2.45 to give 2.58k (26 mg, 80%)
‘H NMR (400 MHz, CDCÏ3): 7.80 (d, 1=8.12, 2H), 7.65 (d, 1=8.20, 2H), 5.76 (s, 1H),
4.16 (m, 2H). 2.91 (m, 1H), 2.65 (m, 2H), 2.41 (m, 1H), 1.64 (m, 2H), 1.43 (s, 9H), 1.38 (s,
6H), 1.21 (m, 2H)
13C-NMR (400 MHz, CDC13): 165.9, 155.1, 139.3, 127.6, 126.0, 125.9, 79.8, 57.4, 46.1,
45.7, 44.8, 42.8, 28.8, 27.3, 24.8
MS (M+1): 415.2, 407.3, 389.2,
4- tl-(4-Isopropyl-benzoylamino)-1-methyl-ethylJ-piperidïne-1-carboxylic acïd tert-butyl
88
HRMS: C21H28N203F3(M+1); Calcd.: 415.2209; found: 415.2199o
9 ,i= NHBoc
N
4-{ 1- 14-(1S-tert-Butoxycarbonylamiuo-ethyl)-benzoylaminoJ -; -methyl-ethyl}-piperï
dïne-1-carboxylic acid tert-butyl ester (2.58h)
According to general procedure B, starting from 2.45 to give 2.58h (21 mg, 81%)
1H NMR (400 IVifiz, CDC13): 7.66 (d, J= 8.04 Hz, 2H), 7.34 (d, J= 7.73 Hz, 2H), 5.84 (s,
1H), 4.83 (m, 2H), 4.10 (m, 2H), 2.66 (m, 1H), 1.66 (m, 2H), 1.43 (s, 18H), 1.41 (d, J 7.61
Hz, 3H), 1.36 (s, 6H), 1.21 (m, 2H)
13C-NMR (400 M}Iz, CDC13): 167.0, 155.4, 155.1, 148.2, 134.8, 127.4, 126.3, 80.0, 79.73,
66.27, 26.97, 50.41, 42.79, 28.87, 28.76, 27.27, 24.85, 23.12, 15.69
HRMS: C27H42N305 (M-1); Calcd.: 489.3124; found: 488.3125
Boc
4- { 1- j(trans-4-Isopropyl-cyclohexanecarbonyl)-amino]-1-methyl-ethyl}-piperidine-1-
carboxylic acid tert-butyl ester (2.58i)
According to general procedure B, starting from 2.45 to give 2.581 (25 mg, 82%)
1H NMR (400 MHz, CDC13): 5.23 (s, 1H), 4.07 (m, 2H), 2.59 (m, 2H), 2.24 (m, 1H), 1.79
(m, 5H), 1.54 (m, 2H), 1.40 (s, 9H), 1.32 (m, 3H), 1.20 (s, 6H), 1.16-0.84 (m, 5H), 0.80 (d, J
=6.78 Hz, 6H),
‘3C-NMR (400 MHz, CDC13): 175.9, 155.1, 79.6, 56.0, 46.9, 44.9, 44.2, 43.6, 42.6, 33.1,
30.4, 29.4, 28.8, 27.2, 24.8, 20.1
HRMS: C23H42N203 (M+1); Calcd.: 394.5912; found: 394.5917
89
Boc -.I
4-{1-Metliyl-1
-t(trans-4-trifluoromethyl-cyclohexanecarbonyl)amino] -ethyl}-piperid
ine-1-carboxylic acid tert-butyl ester (2.58j)
According to general procedure B, starting from 2.45 to give 2.5$j (26 mg, 81%)
1H NMR (400 MHz, CDC13): 5.30 (s, 1H), 4.08 (m, 2H), 2.59 (m, 2H), 2.23 (m, 1H), 1.87
(m, 6H), 1.52 (m, 4H), 1.41 (s, 9H), 1.28 (m, 2H), 1.22 (s, 6H), 1.12 (m, 2H)m, 2H).
13C-NMR (400 IVllTz, CDC13): 174.7, 155.1, 79.71, 56.29, 45.58, 42.64, 28.46, 24.75,
HRMS: C21H35f3N2O3 (M); Calcd.: 420.2612; found: 420.2619.
Boc
N
NH—
4-[1-(4-tert-Butyl-benzenesuffonylamino)-1-methyl-ethyl]-piperïdine-1 -carboxylic acid
tert-butyl ester (2.61])
According to general procedure A, starting from 2.45 to give 2.611 (25 mg, 79%)
‘II NMR (400 MHz, CDC13): 7.80 (d, J= 8.7, 2H), 7.48 (d, J= 8.66, 2H), 4.98 (s, 1H),
4.09 (s, 1H), 2.49 (m, 2H), 1.63 (m, 3H), 1.42 (s, 9H), 1.33 (s, 9H), 1.11 (s, 6H), 1.10 (m.
2H)
‘3C-NMR (400 MHz, CDC13): 156.40, 155.01, 140.83, 127.08, 126.29, 79.78, 59.79, 46.60,
44.4, 43.6, 35.50, 3 1.53, 28.84, 27.01, 25.1.
MS (M+1): 307.1, 260.1, 121.0.
HRMS: C73H37N204S (M-1); Calcd.: 437.2474; found: 437.2466.
o
o
90
4-[1-(4-Acetyl-benzenesnlfonylamino)-1-methyl-ethyl]-piperidine-1 -carboxylic acid tert
butyl ester (2.61m)
According to general procedure A, starting from 2.45 to give 2.61m (11 mg, 79%)
‘H NMR (400 MHz, CDC13): 8.06 (d, 1= 2.47 Hz, 2H), 7.97 (d, J 8.50 Hz, 2H), 4.98 (s,
1H), 1.09 (m, 2H), 2.65 (s, 3H), 2.60 (m, 2H), 1.62 (m, 2H), 1.43 (s, 9H), 1.21 (m, 2H), 1.11
(s, 6H)
‘3C-NMR (400 MHz, CDCI3): 197.26, 155.03, 147.8, 140.0, 129.3, 127.6, 79.9, 60.2, 46.2,
44.4, 43.7, 28.8, 27.3, 27.0, 25.1.
MS (M+1): 425.21, 389.25, 369.15.
HRMS: C21H33N205S (M+1); Calcd.: 425.2110; found: 425.2122.
HNO
HCI
4-Isopropyt-N-(1 -methyl-1 -piperidin-4-yI-ethyl)-benzamïde hydrochtorîde (2.60g)
According to general procedure D and E, starting from 2.58g to give 2.60g (17 mg, 82%)
‘H NMR (400 MHz, CD3OD): 7.65 (d, J= 8.28, 2H), 7.26 (d, J= 8.15, 2H), 5.84 (s, 1H),
3.13 (m, 2H), 2.94 (m, 1H), 2.63 (m, 2H), 2.32 (m, 1H), 2.03 (s, 1H), 1.71 (m, 1H), 1.36 (s,
6H), 1.31 (m, 2H), 1.25 (d, J 6.92, 6H)
‘3C-NMR (400 MHz, CD3OD): 167.1, 152.8, 133.8, 127.2, 127.0, 57.0, 47.4, 44.3, 43.4,
34.5, 28.2, 24.8, 24.2
MS (M+1): 229.2, 154.1, 136.0, 124.1
HRMS: C18H29N20 (M+1); Calcd.: 289.2280; found: 289.2270
HNOH2
HCI
91
, 4-(1S-Amino-ethyl)-N-(1-mcthyl-1-piperidin-4-yl-ethyl)-benzamïde hydrochioride
(2.60h)
According to general procedure D and E, starting from 2.5$h to give 2.60h (11 mg, 79%)
1H NMR (400 MHz, CD3OD): 7.71 (d, J= 8.24 Hz, 2H), 7.44 (d, J 8.13 Hz, 2H), 4.08
(q, J= 6.69 Hz, 4H), 3.14 (m, 2H), 2.62 (m, 2H), 2.42 (m, 2H), 1.70 (m, 2H), 1.39 (s, 9H),
1.38 (d, J= 6.41, 3H)
‘3C-NMR (400 MHz, CD3OD): 169.1, 150.7, 134.7, 127.5, 125.9, 65.9, 56.9, 51.0, 46.3,
42.7, 27.1, 24.3, 23.3
HR1’VIS: C17H28N30 (Mj; Calcd.: 289.2154; found: 289.2156
HNO
HCI
trans-4-(Isopropylcyclohexane)carboxylic acid (1-methyl-1 -pïperïdin-4-yl-ethyl)amide
hydrochioride (2.60i)
According to general procedure D and E, starting from 2.5$i to give 2.60i (14 mg, 78%)
1H NMR (400 MHz, CD3OD): 3.16, (m, 2H), 2.62 (m, 2H), 2.27 (m, 1H), 2.10 (m, 1H),
1.79 (m, 4H), 1.67 (m, 9H), 1.43-1.29 (m, 5H), 1.25 (s, 6H), 1.04 (m, 3H), 0.88 (d, J= 6.79
Hz, 6H),
‘3C-NMR (400 MHz, CD3OD): 156.01, 141.81, 126.73, 125.97, 59.0, 46.28, 46.13, 34.96,
30.55, 27.17, 24.0
MS (M+1): 295.3, 289.1, 154.1, 137.0, 120.0
HRMS: C8H35N2O (M+1); Calcd.: 295.2749; found: 295.2748
HNO
HCI
92
trans-4-(Triftuorometliyl-cyclohexane)carboxylic acid (1-methyl-1 -piperidin-4-yl-ethyl)-
amide hydrochioride (2.60j)
According to general procedure D and E, starting from 2.58j to give 2.60j (17 mg, 82%)
1H NMR (400 MFIz, CD3OD): 3.06 (m, 2H), 2.52 (t, J 11.0 Hz, 2H), 2.22 (m, 3H), 1.98
(m, 2H), 1.86 (m, 2H), 1.62 (m, 2H), 1.51 (m, 2H), 1.33 (m, 4H), 1.24 (s, 6H),
‘3C-NMR (400 MHz, CD3OD): 176.25, 55.87, 46.48, 44.71, 42.75, 41.46, 28.10, 27.27,
24.35, 23.3 1.
HRMS: C16H27N20f3 (M); Calcd.: 320.2075; found: 320.2084.
HN9
HCI
N-(1 -Methyl-1-piperidin-4-yl-ethyl)-4-trifluoromethyl-benzamide hydrochioride (2.60k)
According to generaÏ procedure D and E, starting from 2.58k to give 2.60k (15 mg, 81%)
‘H NMR (400 MHz, CD3OD): 7.80 (d, J= 8.12, 2H), 7.65 (d, J 8.20, 2H), 5.76 (s, 1H),
4.16 (m, 2H), 2.91 (m, 1H), 2.65 (m, 2H), 2.41 (m, 1H), 1.64 (m, 2H), 1.43 (s, 9H), 1.38 (s,
6H), 1.21 (m, 2H).
‘3C-NMR (400 MHz, CD3OD): 167.9, 140.0, 128.1, 125.4, 125.4, 57.1, 46.1, 42.3, 26.6,
24.8, 23.2.
HRMS: C16H21F3N20 (M); Calcd.: 314.1606; found: 314.1609.
HN9
HCI
4-tert-Butyl-N-(1-methyl-1 -pïperïdin-4-yl-ethyl)-benzenesulfonamide hydrochioride,
(2.631)
According to general procedure D and E, starting from 2.611 to give 2.631 (18 mg, 79%)
93
‘H NMR (400 MHz, CD3OD): 7.81 (cl, J= 8.67, 2H), 7.53 (d, J 8.64, 2H), 3.12 (m, 2H),
‘J 2.39 (m, 2H), 1.63 (m, 3H), 1.36 (s, 9H), 1.19 (m, 9H), 1.11 (s, 6H).
MS (M+1): 339.2, 154.1, 126.1.
HRMS: C,8H30N202 S (M+1); Calcd.: 339.2100; found: 339.2106.
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oCHPTER 3
Synthesis of acylguanidïnes as Na/H antiporter inhibitors
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3.1 Na7H antïporters
Most cardioprotective drugs act at different key regulatory cardiovascular cascades to elicit
beneficial effects in ischemic heart disease. t3-Adrenoreceptor antagonists, Œ-adrenoreceptor
antagonists, ACE inhibitors, endothelin antagonists, adenosine-related agents, Ca channel
blockers, Na channel openers, and Na/H exchanger inhibitors are some of the known
agents of clinical importance.”2
Activation of sodium’hydrogen exchangers (NHE) may have an important role in ischemic
ccli death by means of intracellular overload of Na and Ca2. Recent evidence has suggested
that inhibitors of NHE have protective effects on myocardial ischemia both in vivo and in
vitro.
The isoforms are integral plasma membrane proteins, which transport sodium ions in
exchange for protons. Currently there are six known isoforms of NUE. NUE-1 is ubiquitous
and plays a role in maintaining cellular pH, intracellular sodium ion concentration, and celi
volume.3 NUE-2 is present in ail three major gastric epithelial ccli types and is expressed in
the small intestine, colon, and lddney.4’5 NHE-3 is primarily found in renal epithelia,
localized to the apical membrane,6’7 where it has been implicated in the absorption of sodium.
NUE-4 is found in the stomach and the collecting tubule of the renal inner medulla,8 where it
has been proposed to play a specialized role in volume regulation. NHE-5 is present in
several nonepithelial tissues, including brain, spleen, and skeletal muscle, and its role are
unknown.9 NUE-6 is the first intracellular N}{E. It has been identified on recycling
endosomes but not in the inner membrane of mitochondria as primarily assessed.’°
In myocardial ischemia and reperfusion, sodium hydrogen exchangers are activated by
intracellular acidosis in cardiomyocytes leading to an increase in intracellular sodium and
subsequent intracellular calcium overload. The calcium overload provokes severe
arrhythmia» In 1998, Merck (Darmstadt) started clinical trials with a benzyolguanidine
(EMD $531, Figure 3.1) 12 for the treatment in high-risk cardiac patients of acute myocardial
infarction. Clearly, such “small molecule” lead compounds are of great interest, although
efficacy in the treatment of ischemia, and selectivity stiil remain as unresolved issues.
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Furthermore, even though the target has been associated with the Na’ÏH antiporter, and the
subsequent physiological effects are damaging, ifie molecular basis of drug action for these
compounds is flot clear.
3.1.1 NHE-1 structure and cellular Iocalization
Figure 3.1 represents the putative topological model11 for the mammalian N}{E-1, which
consists of two principal domains: a 500—amino acid transmembrane domain and a 315—
amino acid highly hydrophilic carboxyl-terminus cytoplasmic domain. The number of
membrane-spanning units differs according to NHE isoform type, although NHE- 1 contains
12 such spanning regions that are critical for the maintenance its ffinction in terms of proton
extrusion. The hydrophilic cytoplasmic region plays an important role in modulation of the
exchanger, especially tbrough phosphorylation-dependent reactions.’3 This region is NHE
isoform specific, which likely accounts for differential reguÏation by diverse factors.
Figure 3.1 Structure and cellular localization. (Reproduced from Karmazyn, M.; Gan, X. T.;
Humphreys, R. A.; Yoshida, H.; Kusumoto, K. J. Circulation Research. 1999. 85, 777-786.)
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Putative topological model of 81 5—amino acid NHE- 1 showing 12 transmembra-spanning
C segments and hydrophilic carboxyl terminus, with indications of proposed regulatory sites.
Localization of the putative H sensor that accounts for the sensitivity of NHE to pH influx
has flot been confirmed but likely resides in the lipophilic terminus transmembrane region.
3.1.2 Mechanistic basis for NHE învolvement in myocardial ischemic and reperfusion
injury
Because NHE activation is associated with Na influx ([NaJ) the exchanger may also
regulate [Na]i under some conditions. Jndeed, activation of the NEF in the cardiac myocyte
accounts for up to 50% ofthe basal membrane permeability to Na,’4 which may explain the
mechanistic basis for the ability of amiloride an aromatic acylguanidine to decrease the
cardiac effects of digitalis glycosides.15
Increasing [Na] will also affect {Ca2j levels in the cardiac ccli that will affect cardiac
function, especially under ischemia and reperfusion. As illustrated in Figure 3.2, the basis for
N}IE involvement in myocardial ischemic and reperfusion injury reflects a close interaction
between ion-regulatory processes found in the cardiac ceil, especially NI{E, Na-Ca2
exchange, and the Na-K ATPase; indeed, inhibition of the latter during ischemia is an
important prerequisite for NEE involvement in ischemic and reperfusion injury and forrns the
basis for a Natdependent elevation in {Ca2j levels resulting in celi injury. It is known that
changes in pH and in cytosolic Ca2 levels are cÏosely related,16 most likely because Na
entenng via NHE activation is exchanged for Ca2 via Na-Ca2 exchange, leading to an
increase in [Ca2j
Figure 3.2 illustrates the interrelationships between ion-regulatory an rt1 as a
mechanism for NEF involvement in cardiac injury in the ischemic and reperfused
myocardium. Activation of the exchanger occurs as a consequence of various intracellular
and extraceilular factors but most importantly as a resuit of intraceilular acidosis. The
increased influx of Na cannot be removed efficiently because of inhibition of Na-K
ATPase.’4 As a resuit, [Naj levels wili increase, producing elevations in [Ca2j leveis via
Na-Ca2 exchange (NCE).’7 Most ofthe mammalian NHE’s have been cloned.3
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Figure 3.2 NHE involvement in myocardial ischemic and reperfusion injury (according to
Karmazyn, M; Gan, X. T.; Humphreys, R. A.; Yoshida, H.; Kuswnoto, K. J. Circulation
Research. 1999. 85, 777-786)
3.1.3 Ni7W antiporter inhibitors under clinical development
The inhibition of NI-JE-1 demonstrates cardioprotective and antiarrhythmic effect in
myocardial ischemia and reperfusion. In the last decade ifiere has been a tremendous burst of
activity in the pharmaceutical sector to design potent or clinically effective NuE-1 inhibitors.
Several compounds are now in the clinical trials as early as 1998 but none have been
marketed yet (Figure 3.3).
Amiloride was the first of a family of NHE inhibitors. Many NHE inhibitors have been
developed recently, with marked selectivity for the N}IE-1 isoform. These novel NEE
inhibitors include cariporide (HOE-642), eniporide (EMD-96785), and zoniporide (CP-597,
396). Cariporide (HOE-642) was the first selective NI-JE-1 inhibitor discovered, and it is
currently in phase III clinical trials as a potential treatment for myocardial infarction (MI)
and ischemic damage. Another NI-JE-1 inhibitor eniporide is also reported to be in phrase II
clinical trials.18
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Figure 3.3 NaÏH antiporter inhibitors
3.1.4 Functïonal requirements of acylguanidines
It is clear that ail the inhibitors have an acylguanidine unit that appears to be a prerequisite
for biological activity. The methyl sulfonate, although present as an aryl substituent or as a
cyclic variant (Figure 3•4),19 appears to be optional. The majority of the core structures to
which the aryi guanidine is attached are aromatic or heteroaromatic in nature. Although there
are severai NHE- 1 subtypes, oniy one appears to be associated with cardioprotective activity.
Length Le of
longer group is Length L s
parabolically parabolically related
related Essential Essential
for activity for activity
configuration R3 R x
Larger group No effect
is unfavorable
Length “L s
parabolicalty related
Figure 3.4 Functional and structure requirements for activity (Reproducted to Yamamoto, T.;
Hori, M.; Watanabe, I.; Tsutsui, H.; Harada, K.; Ikeda, S.; Ohtaka, H. Chem Pharm. Buti.
1998, 46, 1716)
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3.2 Monocyclic acylguanidines
The opportunities for a chemical approach to drug design in search for an effective and
selective NHE inhibitor are open for exploration. We chose substituted benzoic acids as
templates to synthesize a series of monocyclic acylguandines related to the simple
acylguanidines (Figure. 3.5)
R1
R2
R I •HCI
O NH
R1, R2, R3 = X, aikyl, and H
Figure 3.5 The sfructure ofmonoacylguanidines
The first series consisted of a small library of thirteen compounds with variations in the
aromatic subsistents R1, R2, and R3 from 3.1 to 3.13 (Scheme 3.1). Following an established
protocol, the appropriate benzoyl chloride prepared form the corresponding acid2° was
reacted with fteshly prepared guanidine free base,20’ 21 and the product acidified.22 The
acylguanidines were isolated as hydrochloride saits.
Scheme 3.1 The synthesis ofsubstituted N-acylguanidines 3.1-3.13
R1 R1 R1
R2( 1. NaOMMeOH
R3°H CH2CI2 R3( 2. iN HCI
o O NH2 HCI
3.1-3.13
The synthesis of N-(4-bromo-3-methanesulfonyl-5-methyl-benzoyl)-guanidine 3.14 is shown
in Scheme 3.2.
Scheme 3.2 N-(4-Bromo-3 -methanesulfonyl-5 -methyl-benzoyl)-guanidine 3.17
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SO2CI SO2H
CISO3H Na2SO3, H20
135°C H3C>yH NaOH, r.t, 3 h H3C(0H
0 84% 0 79% 0
3.14 3.15
SO2CH3 SO2CH3
DMF, Mel Br 1. NaOMe, MeOH Br
K2003, r.t H3Cj(03 Guanicne.HC74%
87/ O O NH2HCI
3.16 3.17
Treatment of 4-bromo-3-methylbenzoic acid with chiorosulfonic acid23 gave the
chlorosulfonyl chloride 3.14, which was transformed to the corresponding acid 3.15.
Methylation with Mel and K2C03 afforded the bis-methyl ester 3.16, which was treated with
guanidine to give the intended acylguanidine 3.17 isoiated as the hydrochioride sait.
3.3 Biological resuits
A set of acylguanidines was tested for inhibition of NHE-1 rat ventricular myocytes24
courtesy of Professor Morris Karmazyn (University of Western Ontario). The activities
expressed in 1C50 are shown for the most active compound.
CH3 CI Br CF
ci
— NNH
— NNH2
— NNH2
.— NNH
O NH2 HCI O NH2 HCI O NH2 HCI O NI-I HCI
1C50 = 140 nM 1C50 = 718 nM C50 = 203 nM 1C50 = 63 nM
3.8 3.9 3.10 3.12
Figure 3.6 1C50 values for inhibition.
Typical curves showing reduction of intracelluiar pH shown for Cariporide (the standard) and
the most potent analogues 3.8, 3.9, 3.10, and 3.12 are show in Figure 3.7 (figure 3.7).
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Figure 3.7 Change in pH with concentration.e
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3.4 Experimental notes: (See Chapteri)
For some compounds the carbons resonances do flot match the formulae due to signal
overlap.
NyN H2
HCI
N-Benzoyl-guanidine hydrochioride (3.1)
Benzoic acid (122 mg, 1.0 mmol) was treated with SOC12 (1.3 mL, 18 mrnol) at 120 °C for 2
h. Excess SOC12 was removed with the aid of a water pump, and the resulting acid chloride
was used without further purification. Guanidine hydrochioride (382 mg, 4.0 mmol) was
added to a methanol solution of NaOMe (4.0 mmol, 6 mL), the mixture was refluxed for 30
min. and filtered. The MeOH was removed in vacuo and the residue taken up in 1,2-
dimethoxyethane (15 mL). The acid chloride in 1,2-dimethoxyethane (10 mL) then added to
the guanidine solution (15 mL). Afler the mixture was stirred for 1 h at room temperature, the
inorganic precipitate was removed and the filtrate was evaporated. The residue was purified
by silica gel chromatography (MeOH:CH2C12:NH3H20 9:90:1) to give benzoyl-guanidine as
a white solid (122 mg, 7 1%). HC1 (1 N, 3.0 mmol) was dropped into a stirred suspension of
benzoylacylguanidine (0.75 mmol) in H20 (5 mL), The filtered solution was frozen and then
lyophilized to give the hydrochloride saIt 3.1 (141 mg, 95%).
Mp. 168 oc
‘H NMR (400 MHz, CDOD3): 8.7.98 (d, J= 8.35 Hz, 2H), 7.19 (m, 3H); ‘3C-NMR (400
MHz, CDOD3): 178.1, 164.3, 139.0, 132.3, 129.0, 126.2.
MS (Mj 163.1; HRMS: C8H,0N30 (M); Calcd.: 163.0746; found: 163.0749.
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Br
NyNH
HCIO NH
N-(3-Bromo-benzoyl)-guanidine hydrochioride (3.2)
Same procedure as 3.1 afforded 3.3 (37 mg, 71%)
Mp. 139-142°C
I1 NMR (400 MHz, CDOD3): 8.22 (s, 1H), 7.99 (d, J= 8.65 Hz, 1H), 7.5$ (d, J 8.82 Hz,
1H), 7.30 (dd, J= 8.82, 8.65 Hz, 1H); ‘3C-NMR (400 IVIHz, CDOD3): 177.0, 163.0, 141.2,
138.4, 133.81, 131.86, 129.75, 127.45; HRMS: C8H8BrN3O (M); Calcd.: 240.9851; found:
240.9855
OCH3
H3CO-L
H3CONNH2
HCIO NH2
N- (3,4,5-Trïmethoxy-benzoyl)-guanïdïne hydrochioride (3.3)
Same procedure as 3.1 afforded 3.3 (61 mg, 74%).
Mp: 142-145 °C
‘H NMR (400 MHz, CDOD3): 7.42 (s, 2H), 3.81 (s, 3H), 3.90 (S, 6H); ‘3C-NMR (400
MHz, CDOD3): 173.5, 152.2, 139.1, 134.8, 134.5, 127.3, 106.7, 61.1; MS (M): 253.1,
226.1; HRMS: CiiH,5N3O4(M); Calcd.: 253.1063; found: 253.1071
HCIO NH
10$
N-(4-tert-Butyl-benzoyl)-guanidine Hydrochloride (3.4)Same procedure as 3d afforded 3.4 (59 mg, 74%).
Mp. 165-167 °C
‘H NMR (400 Mhz, CDOD3): 6 7.92 (d, J= 8.65 Hz, 2H), 7.40 (d, J= 8.70 Hz, 2H), 1.32 (s,
9H); 13C-NMR (400 IVlNz, CDOD3): 6 169.1, 153.2, 129.42, 128.6$, 125.55, 124.83, 48.9,
24.8; MS (Mj: 219.1, 218.1, 204.1, 161.1; HRMS: C12H17N30 (M); Calcd.: 219.1372;
found: 219.137$
CH3
NyN H2
O NH
N-(4-Bromo-3-methyl-benzoyl)-guanidïne hydrochioride (3.5)Same procedure as 3.1 afforded 3.5 (34 mg, 7 1%).
Mp. 221-224 oc.
1H NMR (400 MHz, CDOD3): 6 7.93 (d, J= 8.45 Hz, 1H), 7.71 (dd, J 8.52 Hz, 1H), 7.54
(d, J= 8.3 Hz, 1H), 2.41 (s, 3H); ‘3C-NMR (400 MHz, CDOD3): 6 176.45, 163.04, 137.64,
137.58, 132.06, 131.11, 128.25, 127.83, 22.04;MS (M): 255.0, 230.0, 192.2, 136.1; HRMS: c9H10N3Obr (M); calca.: 255.0007; found:
255.0003
cI-
Ny N H2
O NH HCI
N-(4-Chloro-benzoyl)-guanidine hydrochioride (3.6)
Same procedure as 3.1 afforded 3.6 (39 mg, 76%).
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tN ivip.
H NMR (400 MHz, CDOD3): 6 8.0$ (d, J= 8.70 Hz, 2H), 7.35 (d, J 8.68 Hz, 1H);
13C-NMR (400 IVflIz, CDOD3): 6 178.2, 157.3, 131.11, 130.46, 128.87, 128.02,
MS (M): 197.0, 139.0, 127.1, 113.0, 95.0, 77.0; HRMS: C8H8C1N3O (M); Calcd.:
197.0362; found: 197.0356
ci
tÇNNH2
I HCIO NH
N-(3-Chloro-benzoyl)-guanidine hydrochloride (3.7)
Same procedure as 3.1 afforded 3.7 (43 mg, 72%).
Mp. 212-213 oc.
NMR (400 MHz, cDOD3): 6 8.08 (m, 1H), 7.97 (d, J= 7.7 Hz, 1H), 7.46 (m, 1H), 7.34
(m, 1H); ‘3C-NMR (400 MHz, cDoD3): 6 176.80, 163.98, 141.07, 164.02, 130.92, 129.50,
128.91, 127.09; HRMS: C8H8C1N3O (M): Calcd.: 197.0356; found: 197.0349
CH3
ciL
1ïNYNH2
HCIO NH
N-(4-Chloro-3-methyl-benzoyl)-guanidine hydrochioride (3.8)
Same procedure as 3.1 afforded 3.8 (58 mg, 75%).
Mp. 201-202 oc
1H NMR (400 MHz, CDOD3): 6 7.92 (d, J= 1.0 Hz, 1H), 7.83 (d, J= 8.29, 1.6 Hz, 1H),
7.35 (d, J = 8.31 Hz, 1H), 2.39 (s, 3H); 13C-NMR (400 MHz, CDOD3): 6 177.30, 163.74,
137.57, 135.55, 131.43, 128.56, 127.80, 124.3, 19.14; HR11S: C9H11c1N3O (M); Calcd.:
212.0510; found.: 211.0512
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o ciL
ÇÇNNH2
O NH HCI
N-(3,4-Dichloro-benzoyl)-guanidine hydrochloride (3.9)
Same procedure as 3.1 afforded 3.9 (54 mg, 72%).
Mp. 208 oc
‘H NMR (400 MHz, cDoD3): 6 8.21 (d, J= 1.9 Hz, 1H), 7.96 (dd, J= 8.37, 2.0 Hz, 1H),
7.53 (d, J= 8.4 Hz, 1H); ‘3C-NMR (400 IVIFIz, cDoD3): 6 175.56, 163.97, 139.49, 134.87,
131.90, 130.89, 130.07, 128.39; MS (M+1): 232.0, 219.2, 202.1; HRMS: 8H812N3O
(M+1); Calcd.: 232.0044; found: 232.0051.
Br
CkL
HCIO NH
N-(3-Bromo-4-chloro-benzoyl)-guanidine hydrochlorïde (3.10)
Same procedure as 3.1 afforded 3.10 (41 mg, 72%).
Mp. 215-216 °c
1H NMR (400 MHz, cDcl3): 6 8.38 (s, 1H), 8.0 (d, J= 8.1 Hz, 1H), 7.53 (d, J 8.2 Hz, 1H)
‘3C-NMR (400 MHz, cDcl3): 6 175.43, 163.75, 139.47, 136.87, 134.26, 129.92, 129.04,
121.59; MS (M+1): 275.9, 218.9, 154.0, 136.0; HRMS: C8H8Brc1N3O (M+1); calca.:
275.9539; found: 275.9543.
H3C... I?
.NyNH2
HCIO NH2
111
N-(4-Methanesulfonyl-benzoyl)-guanïdine hydrochioride (3.11)
Same procedure as 3.1 afforded 3.11 (28 mg, 74%).
Mp. 205 oc
1H NMR (400 IVIHz, CDC13): 6 8.28 (d, J= 8.6 Hz, 1H), 7.98 (d, J= 8.5 Hz, 1H), 3.15 (s, 3H)
‘3c-NMR(400MHz,cDcl3):6 181.2,162.4,144.3,141.9,130.2,127.1,41.5.
MS (M): 241.1, 218.9, 199.0, 180.9, 147.1, 88.1; HRMS: C9H12N303S (M); Calcd.:
242.05227; found: 242.0523
CF3
ci<L
ÇNNH2
H IO NH
N-(4-Chloro-3-trifluoromethyl-benzoyl)-guanidine hydrochlorïde (3.12)
Same procedure as 3.1 afforded 3.12 (48 mg, 76%).
Mp. 207 oc
‘H NMR (400 MHz, CDC13): 6 8.48 (dJ= 1.72 Hz, 1H), 8.24 (dd, J 8.32, 1.70 Hz, 1H),
7.59 (d, J= 8.34 Hz, 1H); 13C-NMR (400 MHz, CDcl3): 6 175.23, 164.03, 138.33, 134.49,
133.54, 131.30, 128.1793, 128.10, 48.90; MS (M+1): 266.1; URMS: c9H8clF3N3o (M+1);
Calcd.: 266.0234; found: 266.0238.
HCI
O NH
N-(4-Fluoro-benzoyl)-guanidïne hydrochlorïde (3.13)
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Same procedure as 3.1 afforded 3.13 (34 mg, 7 1%).
Mp. 216-217 oc
‘U NMR (400 MHz, CDcÏ3): 8.05 (d, J= 8.21 Hz, 2H), 7.10 (d, J 8.34 Hz, 2H); 13C-
NMR (400 MHz, CDC13): 177.3, 166.4, 135.3, 131.4, 114.7,114.5.
MS: (M+1) 182.1, 154.0, 136.0, 123.0; HRMS: c8H9cN3oF (M+1), Calcd.: 182.0730;
found: Ï 82.0733.
s02c1
BrÇ,
H3Cj(H
o
4-Bromo-3-chlorosulfonyl-5-methyl-benzoic acid (3.14)
4-Bromo-3-methyi-benzoic acid (0.5g, 2.32 mmoi) was added portionwise to chlorosulfonic
acid (0.5 mL, 7.5 mol) in a cooling ice both at such a rate that the internai temperature
remained at 20 °C. The resultant mixture was heated at 140 oc bath temperature for 3 h.
Afier cooling, the mixture was added dropwise to stirred ice water (3.5 mL), and stirring was
continued for an additional 30 min at 10 °c. The precipitate was collected by filtration and
washed with ice water (1 mL) to give crnde 4-chloro-5-(chlorosulfonyl)-3-methylbenzoic
acid 3.14 (0.43 g) which was used directly in the next reaction.
SO2H
H3C(0H
o
4-Bromo-3-methyl-5- carboxybenzenesulfinic acid (3.15)
The crude compound 3.14 was added in portions to a solution ofNa2SO3 (176 mg, 5.2 mmol)
in H20 (0.8 mL) at 15-20 °C. The pH was adjusted to 10 by addition of 32% aqueous NaOH.
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o Stirring was continued for an additional 3 h, then the mixture was left to stand ovemight at
room temperature. Acidification to pH 1 using 25% aqueous HCI at O °C afforded a
precipitate, which was filtered, washed with ice water (0.5 mL) to give crude 4-bromo-3-
methyl-5-carboxybenzenesulfinic acid. The crude was used in the next step without further
purification.
Mp. 137 °C
SO2CH3
BrL
H3CCH3
o
4-Bromo-3-methanesulfonyl-5-methyl-benzoic acid methyl ester (3.16)
Mel (656 iiL, 10.5 mmol) was added to a suspension of 3.16 (0.43 g, mmol) in DMF (6 mL),
and K2C03 (1.59 g, 11.5 mmol) over a period of 1 h with stin-ing, and stirring was continued
ovemight at room temperature. DMF was removed under reduced pressure, and the residue
was treated with water (10 mL), filtered off and washed with water (2 mL). The resulting
solid was air-dried and recrystallized from EtOAc (4 mL) to give 3.16 (0.34 g, 55% overail).
Mp. 146-147 oc
‘H NMR (400 MHz, cDcl3): 8.65 (s, 1H), 8.10 (s, 1H), 3.85 (s, 3H), 3.25 (s, 3H), 2.5$ (s,
3H); 13C-NMR (400 MHz, CDC13): 165.5, 141.2, 136.4, 130.1, 130.0, 128.3, 124.3, 53.1,
42.8, 24.3
SO2CH3
BrL
H3Cff Ny N H2
O NH HCI
N-(4-Bromo-3-methanesulfonyl-5-methyl-benzoyl)-guanïdine hydrochloride (3.1$)
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Free guanidine base was prepared by adding guanidine hydrochioride (382 mg, 4.0 mmol) to
a sodium methoxide (NaOMe) solution, which was prepared from sodium (92 mg, 4.0 mmol)
and MeOH (6 mL). The mixture was reftuxed for 30 min. and filtered. b the filtrate was
added 4-bromo-3 -methanesulfonyl-5-methyl-benzoic acid methyl ester 3.16 (307 mg, 1.0
mmol), and the mixture was stirred for 2.5 h at 50 °C. Afier the mixture was cooled to room
temperature, water (2.50 mL) was added, and the solution was stirred for 30 min and an
additional 30 min with ice cooling while crystallization took place. The product was
collected and recrystallized from MeOH, yielding 3.17 as white crystals (47 mg, 57%)
HC1 (1 N, 0.1 mL) was added into a stirred suspension of 3.17 (25 mg, 1.15 mmol) in F120 (3
mL), The filtered solution was frozen and then lyophilized to give the titie compound as a
solid (28 mg, 95%).
Mp: 260 °c.
1H NMR (400 MHz, CDOD3): 6 2.71 (s, 1H), 8.29 (s, 1H), 2.50 (s, 3H), 3.30 (s, 3H), 2.5$ )s,
3H); 13C-NMR (400 MHz, CDOD3): 6 177.3, 163.7, 137.6, 137.3, 131.4, 128.6, 127.8,
123.5, 47.1, 19.1; HRMS: c10H12BrN3os (M+1), calcd.: 333.9782; found: 333.9779.
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J r rResume
Ma recherche décrit la synthèse de composés hétérocycliques d’importance biologique. En
premier lieu, nous avons fait le design et la synthèse d’un nouvel analogue de type 2-
pyridone basé sur la structure d’un composé antibactérien bien connu, le ABT-719. Un
composé intermédiaire avancé a été atteint, mais des difficultés lors des dernières étapes ont
mené à l’abandon de l’azaquinoline bicyclique désirée.
Le deuxième projet décrit la synthèse d’une petite librairie de 2$ produits consistant en deux
séries de dérivés sulfonamides et amides de pipéridines comme étant inhibiteurs de la Rho-
kinase. Une activité modeste a été trouvée avec un des analogues.
Le troisième projet consiste en la synthèse d’acylguanidines monocycliques comme
inhibiteurs potentiels de canaux Nat’W (Nat’H échangeur, NUE- 1). Basé sur les structures
connues d’inhibiteurs NHE, nous avons synthétisé une petite librairie de dérivés
acylguanidines. Les analyses biologiques ont identifié quatre inhibiteurs potentiels.
Mots clefs: hétérocycle, 2-pyridone, ADN gyrase, pipéridine, Rhokinase inhibiteurs,
acylguanidine, Naiff échangeur (NUE- 1) inhibiteur.
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